THAT'S IN FACT CROSSED THE
BLOOD BRAIN BARRIER.
WE HEARD EARLIER IN THE MORNING
WORK FROM WEST VIRGINIA
UNIVERSITY ABOUT DISRUPTING THE
BLOOD BRAIN BARRIER WITH
ULTRASOUND.
OBVIOUSLY THIS IS NOT UTILIZING
THAT TECHNIQUE BUT W IT DOESN'T
CROSS THE BLOOD BRAIN BARRIER IN
SIGNIFICANT AMOUNTS.
WHAT WE'VE GONE ON TO DO IS AT
THE SINGLE CELL LEVEL UNDERSTAND
HOW IT WORKS THROUGH THREE MAIN
SIGNALING PATHWAYS.
AGAIN THIS IS IMPORTANT BECAUSE
WHEN ONE IS NOWADAYS TRYING TO
DEVELOP A NOVEL PAIN THERAPY,
THERE IS A LOT OF STIGMA, THIS
WAS DISCUSSED YESTERDAY BY THE
STRATEGICS IN TERMS OF
DE-RISKING THE CLINICAL
DEVELOPMENT AND I'LL TOUCH ON
THAT AT THE END OF THE TALK.
ONE OF THE THINGS WE DID EARLY
ON WAS TO CHARACTERIZE THE LACK
OF LIVER INJURY AND ONE CAN SEE
HERE ON THE RIGHT THE LIVER FROM
ANIMALS TREATED WITH VERY HIGH
DOSES OF TYLENOL OR
ACETAMINOPHEN.
YOU CAN SEE THIS WOULD BE THE
EQUIVALENT OF 8, 10, 12 GRAMS.
SO FROM USUALLY ADD OVERDOSE.
THE GROSSLY ABSENT INJURY IN
THOSE LIVERS, THEN WHEN THE
BIOMARKERS, LIVER INJURY
BIOMARKERS ARE LOOKED AT, YOU
CAN SEE THE HIGH RISE IN RED FOR
THE ANIMALS TREATED WITH
ACETAMINOPHEN ARE ABSENT WITH
SRP001.
ALL OF YOU THAT DID HISTOLOGY
REMEMBER THESE SLIDES ON THE TOP
RIGHT THERE WITH ASEAT IN MY
OPINIACETAMINOPHENIS ABSENT AGA.
THEN WHEN WE DO STAINING
DOWNSTREAM OF THE MECHANISM THAT
I'LL SHOW YOU NEXT, WHICH IS NOT
KEY, ONE CAN SEE THAT CENTRAL
NECROSIS -- PRETTY WELL.
SO WE'RE ABLE TO DESCRIBE THE
LIBRARY AS WELL AS DESCRIBE
THESE TWO MECHANISMS NOW IN LATE
2020, AND THE MECHANISM OF
ACTION IS THAT IT DOESN'T
PRODUCE THE METABOLITE MAN KEEP
WHICH IS SHOWN IN 1923 TO BE THE
CAUSE OF LIVER INJURY FROM
ACETAMINOPHEN OVERDOSE.
MORE RECENTLY BY ANOTHER GROUP,
THE DISRUPTION OF THE JUNCTIONS
ARE MAINTAINED THAT ARE
DISRUPTED WITH ACETAMINOPHEN.
SO I WILL GO THROUGH BECAUSE OF
THE BREVITY OF TIME ALL OF THE
WORK REPORTED BY THE NINDS FAST
TRACK, GRANTED WE WERE FORTUNATE
TO RECEIVE THAT CHARACTERIZED
TOXICITY ABSENT THE GOP TOX AS
WELL AS SOME OTHER MECHANISTIC
STUDIES AND JUMP INTO A PHASE
ONE RANDOMIZED TRIAL WE JUST
FINISHED IN DECEMBER 2023, AND
WE ARE DOING THE DRAFT REPORTS
AND FINALIZING THE REPORTS.
SO WE WERE ABLE TO -- IN MIA
MIAMI -- SUBJECTS WITHOUT PAIN
TO BE ABLE TO -- THESE WERE
NORMAL HEALTHY VOLUNTEERS TO BE
ABLE TO REALLY CHARACTERIZE THE
SAFETY TO TOLERABILITY THE PK --
FOOD AND ONE CAN SEE HERE IS
THAT THE DOSE GOES UP, THERE'S A
PROPORTIONAL OR
SUPERPROPORTIONAL INCREASE IN
THE CMAX IN PEAK CONCENTRATION
AT ONE HOUR.
INTERESTINGLY WE HAD A SENSE OF
THIS FROM THE ANIMAL STUDIES,
THERE'S ACTUALLY A BIMODAL
DISTRIBUTION.
WITH A FAVORABLE HALF-LIFE WE'RE
ABLE TO SEE IN THE MAD.
WHAT I'LL POINT TO YOU AT THE
BOTTOM IS IF YOU COULD LOOK AT
THE HALF LIFE OF 10.1 HOUR,
ABOUT 3 TO 4X WHAT'S CURRENTLY
AVAILABLE.
THIS IS BEFORE WE DO MORE
EXTENSIVE EXTENDED RELEASE
FORMULATION WORK ON THE FUTURE
CAPSULE.
SO THESE ARE VERY FAVORABLE
PKs NOT ONLY FOR ACUTE PAIN
BUT WE ALSO FEEL FOR CHRONIC
PAIN WHICH IS OBVIOUSLY THE
LARGE NEED AS 51 MILLION
AMERICANS ARE AFFECTED BY THIS.
SO WE ARE SQUARELY FOCUSED TO DO
THE BEST PHASE 2 STUDY TO ASK
THE QUESTION ABOUT EFFICACY.
THESE ARE DIFFERENT MODELS.
WE ARE CHOOSING TO USE THE
DENTAL MODEL BECAUSE IT'S THE
FASTEST ENROLLMENT YOU CAN SEE
THERE ON THE LEFT IN THE
PUBLICATION, THE HIGHEST
ENROLLMENT 50 TO 60 SUBJECTS PER
CENTER PER MONTH, AND IT ALSO
HAS THE HIGH SENSITIVITY, THE
HIGHEST SIGNAL-TO-NOISE.
THIS IS IMPORTANT BECAUSE AS WE
ALL HAVE DISCUSSED, PAIN IS
SUBJECTIVE AND ONE IS TRYING TO
OBJECTIFY SOMETHING THAT'S
OBJECTIVE.
THE CENTERS HAVE DONE THIS WORK
WITH MERCK, J. & J, GSK OVER THE
YEARS WHEN THEY'VE DONE
REFORMULATED REPURPOSED DRUGS,
SO THERE ACTUALLY IS A FAIRLY
QUANTITATIVE WAY OF DOING THIS
WE JUST DESCRIBED HERE.
THIS IS WHAT THE PHASE 2 TRIAL
DESIGN LOOKS LIKE, HAPPY TO
SHARE THIS WITH ANYONE.
MY EMAIL IS ON THE LAST SLIDE,
IN A COLLABORATIVE WAY TO LOOK
AT THE PRIMARY AND SECONDARY END
POINTS TO TRULY ASK THE
QUESTION, ONE, IS THERE AN
EFFECT COMPARED TO PLACEBO, AND
THEN TWO, IS THERE A
DOSE-RESPONSE BETWEEN LOW AND
HIGH DOSE.
THE COMPARATOR WILL BE EITHER
HIGH DOSE OF ACETAMINOPHEN OR
POSSIBLY VICODIN, 5 MG OF LOW
DOSE ACETAMINOPHEN.
WE WERE FORTUNATE TO RECEIVE
FAST TRACK DESIGNATION FOR ACUTE
PAIN BY FDA IN OCTOBER 2023 AND
I ENCOURAGE ANYONE WORKING ON
NOVEL PAIN THERAPEUTICS TO LOOK
AT THIS MECHANISM BECAUSE IT
REALLY IS A COMMERCIAL
ACCELERANT IN TERMS OF THE
ABILITY OF HAVING MORE FREQUENT
COMMUNICATIONS WITH THE
REGULATORY AGENCY AND ON
AVERAGE, SHAVE ABOUT A YEAR AND
A HALF IN CLINICAL DEVELOPMENT.
TO THAT END WHAT I'LL OUTLINE
HERE IS WHAT THE PATH WOULD LOOK
LIKE, WE HAVE NOT DISCUSSED DATA
WE HAVE ON THE DRG IN
NEUROPATHIC PAIN BECAUSE OF THE
BREVITY OF TIME BUT THAT IS
ANOTHER TARGET, SO WE'RE
SQUARELY FOCUSED NOW ON GETTING
THE RESOURCES SO WE CAN CONDUCT
THE PHASE 2 ACUTE PAIN
RANDOMIZED TRIAL OF 200 SO WE
CAN DEMONSTRATE THESE QUESTIONS
OF EFFICACY AND DOSE-RESPONSE
WHICH I THINK ARE IMPORTANT.
AND THEN CONTINUE THE
DEVELOPMENT.
LASTLY, I'LL JUST MENTION
OBVIOUSLY FOR PARTNERSHIPS,
THESE ARE IMPORTANT THINGS TO DO
TO MAINTAIN A STRONG IP
POSITION.
I'LL FINISH IF YOU'LL ALLOW ME
FOR A MINUTE AND A HALF OR TWO
MINUTES TO REALLY DISCUSS THE
APPROACH THAT US AND MANY OTHERS
HAVE BEEN TAKING THE PAST YEAR
AND A HALF TO TWO YEARS.
THIS IS A SESSION THAT I WAS IN
IN NEW YORK, BIOCEO AND INVESTOR
CONFERENCE IN 2023, THE NEXT IS
IN A COUPLE WEEKS, AND IN THAT
PANEL, DAVE THOMAS FROM BIO WAS
THERE AND HE PRODUCED THIS
REPORT WE'VE ALLUDED TO A LITTLE
BIT IN THIS CONFERENCE.
THE DERTH OF INVESTMENT IN
INNOVATIVE CANDIDATES SAY
COMPARED TO ONCOLOGY, AND CAN
YOU SEE HOW FLAT IT IS.
AND WHAT I WOULD THINK, WHAT I
SAY UNDERSTANDING THE HEAL
THERAPIES THAT ARE BEING
DEVELOPED IN HAVING PRECIPITATED
THE LAST FEW DAYS AND FROM THE
PAST YEAR IS THAT I THINK WE'RE
ON THE CUSP OF INNOVATION AND
I'M HOPEFUL THAT IT IS POSSIBLE
IN THE NEAR FUTURE THESE TARGETS
AND CANDIDATES WILL TRANSLATE TO
NOVEL SOLUTIONS FOR ACUTE AND
CHRONIC PAIN.
OBVIOUSLY WE ALL KNOW ABOUT THE
VERTEX NEWS.
ONE OF THE TW TWO TRIALS SHOWED
INFERIORITY, THE OTHER WAS NOT
ABLE TO MEET THAT END POINT.
THE MEDIA STILL TALKS ABOUT THE
GREAT NEED WE NEED AS A NATION
FOR NOVEL NEW OPIOID.
I THINK THE AIM IS TO --
RIGOROUS RANDOMIZED TRIAL TO
LOOK AT THE EFFICACY.
TO THAT END, THIS IS IN
SAN DIEGO IN OCTOBER WITH
DR. KOROSHETZ AND DR. BILL
SCHMIDT AT HIS CONFERENCE.
YOU CAN SEE DR. MIKE KOSHINSKI
AND DR. SHARON HERTZ, SEVERAL
PIPELINES, SEVERAL NEW TARGETS
WERE DISCUSSED OVER TWO DAYS
WHICH I THINK ARE IMPORTANT.
HERE'S WHERE WE'RE TARGETING, WE
WERE IN A SESSION BEFORE LUNCH
ON DIFFERENT TARGETS AND I THINK
THESE ARE IMPORTANT.
YOU CAN SEE THE NUMBER OF PAIN
TRIALS IN 2023, SO I THINK THERE
IS A LOT OF OPTIMISM TO
HOPEFULLY TRANSFORM PAIN.
I WILL JUST END THAT IN BIO IN
JUNE, I WILL CHAIR THIS SESSION
ON NEW PAIN THERAPEUTICS AND
I'LL BRING SOMEONE FROM NIH
LEADERSHIP AND TRY TO BRING IN
THE STAKEHOLDERS THAT WE CAN GET
HOPEFULLY POSITIVE ENGAGEMENT TO
HELP PATIENTS FOR WHOM WE'RE
DOING THIS WORK FOR.
THANK YOU.
>> THANK YOU, DR. BAZAN.
NEXT WE'RE GOING TO MOVE TO HEAR
FROM DR. KATHERINE CHONG FROM
THE MAYO CLINIC, SO I WANT TO
WELCOME HER TO THE STAGE.
>> THANK YOU VERY MUCH.
THANK YOU VERY MUCH FOR THE KIND
INTRODUCTION.
SO BEFORE I BEGIN, I'D LIKE TO
THANK THE ORGANIZERS FOR THE
OPPORTUNITY TO PRESENT.
IT'S TRULY A PLEASURE BEING
HERE.
I ALSO WANT TO SAY I'M HONORED
AND GRATEFUL TO BE SELECTED AS A
RECIPIENT FOR THE TRAILBLAZER
AWARD.
IT MEANS A GREAT DEAL TO ME.
THANK YOU.
SO I'LL BE TALKING ABOUT A
BIOMARKER SIGNATURE FOR
PREDICTING POST-TRAUMATIC
HEADACHE PERSISTENCE.
HERE ARE MY DISCLOSURES.
I RECEIVED RESEARCH SUPPORT FROM
THE NIH, DOD, AS WELL AS AMGEN.
AND POST-TRAUMATIC HEADACHE.
SO WHY ARE WE INTERESTED IN IT,
AND WHY DO WE WANT TO TRACK
RECOVERY AND WHAT IS
POST-TRAUMATIC HEADACHE IN THE
FIRST PLACE?
SO POST-TRAUMATIC HEADACHE IS
PROBABLY THE MOST COMMON SYMPTOM
FOLLOWING MILD TRAUMATIC BRAIN
INJURY AND IS ALSO THE MOST
DISABLING SYMPTOM.
THERE'S A LOT OF OVERLAP BETWEEN
POST-TRAUMATIC HEADACHE
PHENOTYPICALLY WITH MIGRAINE.
IN FACT IF YOU SAW A PATIENT YOU
DIDN'T KNOW THAT THAT PATIENT
HAD A CONCUSSION, YOU PROBABLY
WOULD MISTAKE THEM FOR SOMEBODY
WITH MIGRAINE.
THERE ARE A COUPLE OF RISK
FACTORS THAT ARE ASSOCIATED WITH
DEVELOPING ACUTE POST-TRAUMATIC
HEADACHE, WHICH IS A HISTORY OF
MIGRAINE, AS WELL AS FEMALE SEX.
AND WE ALSO KNOW THAT DEVELOPING
PERSISTENT POST-TRAUMATIC
HEADACHE, WHICH ARE HEADACHES
THAT LAST LONGER THAN THREE
MONTHS, ARE ASSOCIATED WITH
SIGNIFICANTLY INCREASED
LONG-TERM DISABILITY AS WELL AS
HEALTH BURDEN.
SO WHAT WE DON'T KNOW, REALLY,
IS, AND THAT'S A HUGE PROBLEM,
IS WHY DO PEOPLE, AFTER HAVING A
CONCUSSION, THEY GET HEADACHES
AND THEY RECOVER QUICKLY, RIGHT?
MAYBE THEY HAVE HEADACHES A
COUPLE OF DAYS, THEN THEY GO
AWAY, NEVER TO RETURN.
AND WHY DO SOME OTHER PEOPLE
DEVELOP PERSISTENT HEADACHES
THAT LAST FOR DAYS AND WEEKS AND
SOMETIMES YEARS TO COME?
AND THAT'S REALLY A CONUNDRUM
AND THAT PUTS PHYSICIANS IN A
REALLY BAD SPOT, BECAUSE WE KNOW
THAT ADMINISTRATION OF
MEDICATION WORKS BEST WHEN
ADMINISTERED AT THE EARLIEST
POSSIBLE TIME POINT, BUT WE
DON'T WANT TO GIVE MEDICATION TO
THOSE WHO CAN RECOVER ON THEIR
OWN, WHO DON'T NEED IT, RIGHT?
BECAUSE ALL MEDICATIONS HAVE
SIDE EFFECTS.
SO THIS IS REALLY THE GOAL, AND
THAT WAS THE REASON WE WERE
HOPING TO DEVELOP BIOMARKERS
THAT THEN ALLOW US TO PREDICT
WHO'S GOING TO RECOVER AND WHO
IS GOING TO BE AT HIGH RISK FOR
DEVELOPING PERSISTENT
POST-TRAUMATIC HEADACHE.
SO THIS IS HOW WE ORGANIZED THE
STUDY.
WE WERE FUNDED IN 2019.
PATIENT WERE ENROLLED ACUTELY
AFTER TBI, THEY COMPLETED
BASELINE IMAGING DATA, IT WAS A
LONG BATTERY THAT I'LL SHOW
LATER, AND THEN THEY CAME BACK
AT THREE MONTHS AND SIX MONTHS.
WE ALSO GAVE PATIENTS AN APP TO
COMPLETE THEIR DAILY HEADACHE
DIARY.
AND THEY ALSO SUBMITTED SPEECH
SAMPLES I EVER THREE EVERY THREN
APP.
SO WE ASKED PATIENTS IN OUR
HEALTHY CONTROLS TO SUBMIT A LOT
OF DATA.
AND SO YOU CAN SEE THAT JUST
COMPLETING THE QUESTIONNAIRES,
AND I THINK THERE WERE 12 OR 13
ON THERE, TOOK ABOUT 60 MINUTES.
SO THAT'S WAY TOO LONG,
CLINICALLY NOT USEFUL, BUT WE
WANTED TO SPREAD A WIDE NET AND
THEN SELECT THOSE ONES WITH HIGH
UTILITY AS WE PRUNED DOWN THIS
HEADACHE AND QUESTIONNAIRE
BATTERY.
SO HERE'S SOME OF OUR EARLIER
RESULTS.
SO WE TOOK ALL THE
QUESTIONNAIRES AND ALL THE
FEATURES FROM THE QUESTIONNAIRES
AT BASELINE, AND WE WANTED TO
SEE THE PREDICTIVE VALUE OF JUST
THE QUESTIONNAIRE ONLY.
WE ACTUALLY FOUND IT WAS QUITE
GOOD.
IT HAD AN AUC OF .72, AND
INTERESTINTERESTINGLY, WHEN WE D
DOWN AND PRUNED DOWN THIS
QUESTIONNAIRE TO ONLY THOSE THAT
HAD PREDICTIVE ACCURACY, WE
ENDED UP WITH THREE
QUESTIONNAIRES AND FIVE
QUESTIONS FROM THESE THREE
QUESTIONNAIRES.
INTERESTINGLY, THESE QUESTIONS
RELATED TO PHYSICAL, COGNITIVE
AND EMOTIONAL SYMPTOMS FROM THE
SPORTS CON SUGGESTS ASSESSMENT
TOOL.
THERE WE GOT THE TOTAL SCORE, AS
WELL AS NUMBER OF SUBSCORES.
AND ALSO THE TOTAL SCORE FROM
THE PAIN CATASTROPHIZING SCALE.
NOT A BIG FAN OF THE NAME OF
THAT SCALE, BUT NEVERTHELESS, IT
WAS REALLY INTERESTING TO US
THAT THE SUBDOMAIN SCORE OF
HELPLESSNESS REALLY POPPED UP
AND CONTRIBUTED TO IDENTIFYING
THOSE WITH PERSISTING HEADACHE.
AND THEN LASTLY, THE TRAIT
ANXIETY INVENTORY SCALE WHICH
MEASURES GENERAL ANXIETY.
SO AGAIN WHEN WE PRUNED IT DOWN,
WE WERE ABLE TO RETAIN
0.72 ACCURACY, WHICH MADE US
QUITE HOPEFUL.
AND WE THEN THOUGHT, OKAY, LET'S
ADD SOME OF THE STRUCTURAL
IMAGING MEASURES, AGAIN GIVEN AT
BASELINE.
SO FROM THE T1 WEIGHTED SCAN, WE
PARWE -- WHEN WE ADDED THAT TO
THOSE THREE QUESTIONNAIRES, WE
WERE ABLE TO INCREASE THROUGH
PREDICTIVE POWER TO 0.8.
SO WE ALSO HAD PATIENTS SUBMIT A
SPEECH SAMPLE, AND WE WERE ABLE
TO EXTRACT SPECIFIC FACTORS FROM
THERE, AND ONE IS A SPEAKING
RATE AND PAUSE RATE.
AND THIS IS SOMETHING THAT OUR
STUDY COORDINATOR DANNY SMITH
WAS VERY INTERESTED IN.
AND YOU CAN SEE JUST FROM THOSE
SCALES ON THE LEFT, ON THE
SPECTRAS, THAT AS PATIENTS HAD
MODERATE HEADACHE, THEIR
SPEAKING RATE BECAME MUCH LONGER
TO SAYING A SPECIFIC SENTENCE.
IT WAS REALLY INTERESTING TO US
THAT WHEN WE COMPARED THE DATA
TO HEALTHY CONTROLS, NOT ONLY
WERE THERE THESE DIFFERENCES
WITH PATIENTS WITH ACUTE
POST-TRAUMATIC HEADACHE BEING
SLOWER, BUT WHEN WE COMPARED THE
DATA TO MIGRAINE, AGAIN, VERY
PHENOTYPICALLY SIMILAR TO
PATIENTS WITH ACUTE
POST-TRAUMATIC YO HEADACHE, WE
STILL FOUND THAT COMPARED TO
HEADACHE-FREE STATE OR MILD
HEADACHE OR MODERATE HEADACHE,
THAT OUR PATIENTS WITH ACUTE
POST-TRAUMATIC HEADACHE WERE
STILL SLOWER THAN MIGRAINE.
AND IT'S INTERESTING, AGAIN,
BECAUSE PHENOTYPICALLY, THEY'RE
SO SIMILAR, THAT IT COULD
INDICATE THAT ON THE LEVEL OF
THE PATHOPHYSIOLOGY, THAT THERE
ARE DIFFERENCES RELATED TO THE
HEADACHE AS WELL AS THE
CONCUSSION.
NOW AGAIN THE WHOLE GOAL WAS TO
COMBINE OUR DATA, TO ENSEMBLE
THE DATA.
SO WE AGAIN DREW FOR MORE
IMAGING FEATURES.
WE ADDED THE QUESTIONNAIRES AND
THE SPEECH SAMPLES, AND WANTED
TO SEE HOW MUCH AND HOW MANY
DAYS OF SPEECH SAMPLES WILL BE
NECESSARY TO THEN BE ABLE TO
PREDICT RECOVERY AT THREE
MONTHS.
AND WHAT WE FOUND IS WE RECEIVED
AN ACCURACY OF 0.8 BY ADDING SIX
WEEKS OF SPEECH DATA.
THEN MY COLLEAGUE FROM GEORGIA
TECH SAID, SUGGESTS THAT, YOU
KNOW WHAT, LET'S JUST TAKE THE
EASY MEASURES AND COMBINE THEM.
THOSE THREE QUESTIONNAIRES.
LET'S SEE HOW MUCH DAILY DIARY
DATA NEEDS TO BE ADDED TO THAT.
THAT'S EASY TO COLLECT.
TO SEE IF WE CAN IMPROVE UPON
THAT ACCURACY.
AND WHAT WE WERE EXTRACTING IS
20 VARIABLES WHICH WERE REALLY
20 BINARY QUESTIONS FROM THE
ELECTRONIC HEADACHE DIARY, AND
AGAIN, WE LOOKED AT OUR END
POINT OF IMPROVEMENT AT THREE
MONTHS AND FOUND THAT ABOUT
SEVEN WEEKS OF DIARY WAS
NECESSARY TO INCREASE OUR
ACCURACY THEN TO 0.88.
YOU SEE EVEN IF PATIENTS SKIPPED
A COUPLE OF DAYS, THAT DIDN'T
SEEM TO REDUCE THE ACCURACY BY
VERY MUCH.
BUT WHAT'S REALLY INTERESTING TO
US, THAT WE THOUGHT HEADACHE
FREQUENCY WOULD BE AT THE TOP
FEATURE TO PREDICT HEADACHE
PERSISTENCE BUT IT WASN'T.
THERE WERE MORE FEATURES RELATED
TO HOW DISABLING AND HOW INTENSE
THE HEADACHE WAS.
SO MORE FEATURES RELATED TO
HEADACHE BURDEN.
THIS IS ALSO A STUDY THAT WAS
DEVELOPED BY AN ASU STUDENT AND
WHO, AGAIN, COMBINED SPEECH DATA
WITH IMAGING DATA.
THIS TIME IT WAS T2 STAR DATA
WHERE WE LOOKED AT IRON
ACCUMULATION, AND SO FAR THE
BEST ACCURACY IS 86.6% IN
PREDICTING PATIENTS THAT RECOVER
FROM THOSE WHO DO NOT RECOVER.
WE'RE AT THE R33 PHASE NOW,
WHERE WE'RE HOPING TO HAVE GREAT
VALUE AND BE CLINICALLY USEFUL.
NOT ALL PATIENTS ARE GOING TO
HAVE ALL DATA.
SOME PATIENTS MAY HAVE A
T1 WEIGHTED SCAN, SOME DON'T.
SOME PEOPLE MAY HAVE COMPLETED
SOME QUESTIONNAIRES, SOME DON'T.
AND SO HERE YOU COULD CLICK ON
THOSE DATA THAT ARE AVAILABLE
AND THEN THE ALGORITHM WOULD
YIELD THE PROGNOSIS OF RECOVERY.
SO WITH THAT, I'D LIKE TO THANK
OUR COLLABORATORS FROM GEORGIA
TECH, JING LI AS WELL AS HER
TALENTED STUDENTS, FROM THE VA,
CATHERINE ROSS, SHANNON HARRIS
FROM ASU, AND THEIR INCREDIBLY
STUDENTS AND POSTDOCS.
MY COLLEAGUES FROM MAYO CLINIC.
AS WELL AS OUR COORDINATORS.
THE SUCCESS OF THE STUDY HINGES
ON COLLABORATION AND THE
INNOVATIVE SPIRIT, AND I AM VERY
GRATEFUL FOR YOUR CONTINUED
SUPPORT AND DEDICATING YOUR TIME
TO THE STUDY.
THANK YOU.
>> THANK YOU, DR. CHIONG.
CHONG.
NEXT WE'RE GOING TO HEAR FROM
MR. JACOB COVERSTONE OF
NEUROVATIONS EDUCATION.
>> I KIND OF WISH THERE WERE
FEWER PEOPLE LEFT IN THE WORD.
DON'T FAULT ME IF I STUMBLE.
WE ARE PART OF THE INITIATIVE TO
HELP CULTIVATE, DEVELOP AND
RETAIN THE NEXT GENERATION OF
PAIN RESEARCHERS.
SO WE HAVE BEEN -- WHAT WE HAVE
CREATED IS BOTH AN IN-PERSON AND
ONLINE COMPONENT TO TRY TO
CENTRALIZE A BUNCH OF RESOURCES
AND TO BRING THE ENTIRE
COMMUNITY ACROSS THE SPECTRUM OF
BASIC CLINICAL TRANSLATIONAL
PERSONS WITH LIVED EXPERIENCE,
RESEARCH ADMINISTRATORS, ALL
INTO ONE NETWORK TO BROADEN YOUR
COLLABORATIVE SPHERE.
IF YOU REMEMBER NOTHING ELSE,
PAINREACHERS.COM, IF YOU'RE IN
THIS ROOM, YOU BELONG IN THE
NETWORK.
PAINRESEARCHERS.COM.
IT IS ONE PLACE, ONE COMMUNITY
THAT AK GATE AGGREGATES A LOT OF
INFORMATION.
SOME IS JUST FOR THIS COMMUNITY
AND IS PART OF HOPEFULLY DOING A
GOOD JOB OF SUPPORTING THOSE WHO
ARE TRYING TO SOLVE THESE GREAT
CHALLENGES.
WE'VE GOT ABOUT 2,000 MEMBERS IN
THE NETWORK AT THE MOMENT,
ABSOLUTELY FREE TO JOIN,
PAINRESEARCHERS.COM, YOU CAN GO
THERE.
WHEN YOU ACTUALLY CREATE YOUR
PROFILE, EVERYBODY IS VETTED,
IT'S INVITE OR APPROVAL ONLY, SO
IT IS A CLOSED NETWORK.
THIS IS NOT INSERT OTHER SOCIAL
NETWORK HERE.
WHENEVER YOU JOIN, YOU'LL
SELF-IDENTIFY AS BASIC CLINICAL
TRANSLATIONAL IF YOU YOURSELF
ARE A PERSON WITH LIVED
EXPERIENCE, ALL OF THIS
INFORMATION IS TAILORED SO THAT
YOU CAN HELP DETERMINE
RELEVANCY.
MY SLIDES ARE OUT OF ORDER.
OF THOSE PERSONS THAT YOU WOULD
SEEK TO COLLABORATE WITH AND
ALSO TO BE FOUND.
WE'VE GOT DIFFERENT INTEREST
GROUPS THROUGHOUT THE PLATFORM,
BOTH THOSE TO HELP YOU
ADMINISTER YOUR OWN PROJECTS AND
GRANTS BUT ALSO FOR
SUBCOMMUNITIES OF INTEREST THAT
CAN HELP YOU ANSWER AND SOLVE
SOME OF THESE GREAT CHALLENGES.
IF YOU USE TO ACTUALLY
ADMINISTER YOUR OWN PLATFORM,
HERE'S AN EXAMPLE OF WHAT REJOIN
IS DOING, IT CAN BE YOUR CENTRAL
RESOURCE HUB.
YOU CAN COLLABORATE, YOU CAN
COMMUNICATE WITH OTHERS IN YOUR
PROJECTS.
YOU CAN SCHEDULE ALL YOUR
MEETINGS THROUGH IT.
THEY TOOK REGISTRATION FOR THEIR
ANNUAL MEETING THROUGH THE
PLATFORM.
IF YOU'RE AN ADMIN, YOU CAN
ACTUALLY USE THIS INSTEAD OF
MAILCHIMP OR SOMETHING ELSE TO
ACTUALLY TELL IF THOSE IN THE
STUDY ARE OPENING YOUR MESSAGES
YOU'RE SENDING THEM, AND REALLY
INTEGRATE WITH THE REST OF THE
RESEARCH COMMUNITY AND LET THEM
KNOW WHAT YOU'RE DOING ON.
YOUR OWN PROFILE, IT'S AN
OPPORTUNITY TO SHOWCASE WHAT
YOUR EXPERTISE IS, TO UPLOAD
YOUR BIOSKETCH.
EVERYTHING IS CUSTOMIZED TO THIS
COMMUNITY.
A LOT OF THE INFORMATION YOU
WOULD HAVE TO FILL IN ERA
COMMONS ABOUT ANY OF YOUR
COLLABORATORS IS ALSO GOING TO
BE ADDED TO THIS NETWORK.
IF YOU SO WISH.
YOU CAN SHOWCASE YOUR EXPERTISE,
LINK UP YOUR OWN STUDIES AND
PROJECTS AND UNLIKE ON THE NIH
REPORTER WHERE YOU REALLY JUST
SEE THE PO AND THE PI ON ANY
STUDY, YOU CAN LIST YOUR ENTIRE
RESEARCH TEAM HERE.
YOU CAN GET THOSE WHO ARE DOING
ADMINISTRATIVE WORK CREDIT FOR
DOING THAT WORK AS WELL.
SHOWCASE EVERYBODY'S EXPERTISE.
YOU CAN EVEN START GROUP
MESSAGES BETWEEN THE ENTIRE
GROUP IF YOU HAVE A DIFFUSED
NETWORK.
YOU CA CAN ALSO GET A LITTLE BIF
RECOGNITION.
THIS IS REAL, BY THE WAY.
THE AWARD IS ABOUT YAY TALL.
WE HAVE FIVE CATEGORIES THIS
YEAR.
APPLICATIONS ARE OPEN.
DEADLINE IS MARCH 18TH.
PLEASE SUBMIT.
THOSE WILL BE HANDED OUT AT THE
SECOND ANNUAL PURPOSE MEETING
FOR PAIN RESEARCHERS.
THIS IS AN INTERESTING KIND OF
FUN NOVEL PROGRAM, NOT LIKE ANY
OTHER PAIN RESEARCH MEETING
YOU'VE GONE TO.
WE FOR EXAMPLE HAD A WONDERFUL
POSTER SESSION WHERE NONE OF THE
FEEDBACK WAS ABOUT YOUR
RESEARCH, IT WAS ALL ABOUT HOW
YOU WERE COMMUNICATING THAT
RESEARCH.
WE'RE TRYING TO FOCUS ON THE
SKILLS NOT TO NECESSARILY MAKE
YOU BETTER AT YOUR RESEARCH,
YOUR HOME INSTITUTION, YOUR
MENTORS ARE ALL WORKING HARD TO
DO THAT.
WE'RE TRYING TO MAKE YOU A
BETTER RESEARCHER TO HELP GIVE
YOU THAT NETWORK AND THOSE
SKILLS THAT ARE GOING TO HELP
YOU STAY IN THIS FIELD AND
CONTINUE DOING YOUR WORK FOR A
LONG TIME AND TO THRIVE.
SO A LOT OF THAT MEETING IS
BASED OFF GIVING FEEDBACK FOR
COMMUNICATION STRATEGIES,
WORKING IN INTERDISCIPLINARY
MATRIX TEAMS, AND YOU GET
FEEDBACK ON HOW YOU WRITE YOUR
AIMS PAGES, HOW YOUR BIOSKETCH
IS DRAFTED.
SUPPORT STRATEGIES FOR EARLY ADD
MID CAREER RESEARCHERS THIS
YEAR, AGAIN, COMPLETELY FREE,
AND WE WILL BE LIVESTREAMING AS
WELL.
ONCE YOU'RE IN THE NETWORK, YOU
CAN REGISTER.
THERE'S ALSO A LOT OF ONLINE
LEARNING, WE HAVE A FUN SEERS
CALLED GET TO KNOW YOUR NIH IC
WHERE IS WHERE WE INTERVIEW EACH
INSTITUTE OR CENTER ONE BY ONE
TO TALK ABOUT THE NUANCES OF
FUNDING PAIN RESEARCH, WHAT
THEIR PRIORITIES ARE, HOW THEIR
INSTITUTE IS DIFFERENT THAN
OTHERS, AND REALLY TRY TO TEASE
APART THESE NUANCES AND
DIFFERENCES.
IT'S ACTUALLY REALLY ENGAGING
AND, I'VE GOT TO SAY, KIND OF
FUN.
THOSE ARE HAPPENING MONTHLY.
WE ALSO DO KIND OF THESE EXPERT
DEEP DIVES OF WHAT HAS YOUR
CAREER TRAJECTORY BEEN LIKE,
WHAT ARE SOME OF THE BARRIERS
YOU'VE FACED IN YOUR CAREER.
SOON I THINK WE'LL BE POSTING
THE RECORDING OF ONE WE DID LAST
MONTH FOR TRANSITIONING FROM A K
TO AN R01, FOR EXAMPLE.
THERE'S AN APP FOR THAT.
THERE'S A QR CODE AVAILABLE.
OUT IN THE LOBBY.
YOU CAN SCAN THAT, DOWNLOAD THE
APP.
AT THIS POINT, ALMOST DAILY, I'M
GETTING MESSAGES ON THERE THAT
WE'RE ABLE TO COMMUNICATE WITH,
TROUBLESHOOT, SUPPORT OTHER
PEOPLE AND IT'S JUST MUCH MORE
CONVENIENT.
AGAIN, THERE'S A BOOTH IN THE
HALLWAY.
PAINRESEARCHERS.COM.
JOIN THE NETWORK, LET US KNOW
WHAT WOULD HELP YOU, AND
PARTICIPATE.
TEU TO EVERYBODY AT NEUROVATIONS
EDUCATION, EVERYBODY IN THE BACK
THERE, AND EVERYBODY FOR HELPING
AND SUPPORTING THE TIME TO DO
THIS.
THAT'S ALL.
>> THANK YOU, MR. COVERSTONE.
SO NOW I WANT TO WELCOME TO THE
STAGE DR. KATHRYN HAWK OF YALE
UNIVERSITY.
>> THARNT THANKS SO MUCH.
I'MAGE EMERGENCY PHYSICIAN
PRACTICE AT YALE UNIVERSITY AND
AM JUST REALLY, REALLY THRILLED
TO BE HERE.
AND AS YOU'RE GOING TO SEE
TODAY, IT'S REALLY GOING TO
BE -- I'M GOING TO BE TALKING
ABOUT SOME WORK THAT A LARGE
GROUP OF US HAVE DONE TO REALLY
HELP LEVERAGE THE ED TO IMPROVE
CARE FOR PATIENTS WITH OPIOID
USE DISORDER.
I HAVE NO CONFLICTS OF INTEREST
TO DISCLOSE.
SO WHY FOCUS ON THE ED?
VERY OBVIOUS TO SOME PEOPLE BUT
TO SOME PEOPLE IT MIGHT REQUIRE
A LITTLE BIT MORE THOUGHT ON WHY
WE WOULD THINK THAT THIS IS THE
RIGHT PLACE TO IDENTIFY AND
START PEOPLE ON TREATMENT FOR
OPIOID USE DISORDER.
WE CERTAINLY KNOW WE SEE PEOPLE
IN THE ED AFTER OVERDOSE, SKIN
AND SOFT TISSUE INFECTIONS,
ABSCESSES, THEY COME IN AFTER
INJURIES, THEY COME IN IN
WITHDRAWAL, WHEN THEY CAN'T FIND
ANY OTHER TREATMENT IN THEIR
LOCAL HOME COMMUNITY.
ONE OF THE THINGS THAT MY MENTOR
WHO IS HERE SOMEWHERE WHO YOU'LL
HEAR ABOUT THROUGHOUT THIS TALK
REALLY -- TO HELP FIGURE OUT HOW
WE CAN IMPROVE OUR CARE OF FOLKS
IN THE ED.
SO I'M ACTUALLY GOING TO -- I'VE
HAD THE PRIVILEGE AS A HIGHLY
COLLABORATIVE RESEARCHER OF
BEING INVOLVED IN SORT OF FOUR
DIFFERENT HEAL STUDIES OVER THE
COURSE OF THE LAST FOUR YEARS.
AND SO I'M GOING TO TALK A
LITTLE BIT ABOUT THOSE ON A
VERY, VERY HIGH LEVEL.
OR GOING TO TRY TO OVER THE NEXT
EIGHT MINUTES OR SO.
SO THIS IS THE BASIS FOR ALL OF
OUR WORK ON IMPLEMENTING ED
INITIATED BUPRENORPHINE IN THE
EMERGENCY DEPARTMENT.
PUBLISHED IN JAMA IN 2015 THAT
SHOWED THAT PEOPLE WHO COME IN
TO THE EMERGENCY DEPARTMENT WITH
UNTREATED OPIOID USE DISORDER,
IF THEY'RE RANDOMIZED TO RECEIVE
TREATMENT, IF THEY WERE
RANDOMIZED TO RECEIVE
BUPRENORPHINE AND A REFERRAL FOR
TREATMENT, WERE ALMOST TWICE AS
LIKELY TO BE IN TREATMENT AT 30
DAYS COMPARED TO THOSE WHO WERE
RECEIVING JUST A STANDARD
REFERRAL WHICH AT THE TIME WAS
STANDARD OF CARE FOR THE
EMERGENCY DEPARTMENT.
WE KNOW TREATMENT ENGAGEMENT IS
ONE OF THE MOST IMPORTANT THINGS
WE CAN DO, SO THIS REALLY
STARTED I GUESS STARTED THE
INSIGHT OF KNOWING THAT WE
NEEDED TO FIGURE OUT HOW TO DO
BETTER IN THE EMERGENCY
DEPARTMENT, HOW TO GET OUR
CLINICIANS TO THINK ABOUT
INTEGRATING THIS INTO THEIR
CLINICAL PRACTICE.
SO THROUGH THE CLINICAL TRIALS
NETWORK, WE LAUNCHED TWO
SEPARATE IMPLEMENTATION STUDIES.
THERE'S A LOT OF JARGON ON THESE
SLIDES, BUT SO ONE IS PROJECT ED
HEALTH WHICH IS A CLINICAL
TRIALS NETWORK 69.
AND THIS IS AN IMPLEMENTATION
STUDY AND FOUR URBAN ACADEMIC
EMERGENCY DEPARTMENTS.
THE SECOND STUDY IS ED CONNECT
WHICH SL ETN79 AND 79-A1, HIGH
NEED, LOW RESOURCE EMERGENCY
DEPARTMENTS.
THINKING ABOUT THOSE RURAL
EMERGENCY DEPARTMENTS, CRITICAL
ACCESS HOSPITALS, COMMUNITY
HOSPITALS THAT HAVE DIFFERENT
STAFFING STRATEGIES AND PUBLIC
SAFETY NET HOSPITALS.
SO THE IDEA WAS TO THINK ABOUT
HOW WE CAN SUPPORT
IMPLEMENTATION OF ED-INITIATED
BUPRENORPHINE ACROSS THESE SEVEN
DIFFERENT EMERGENCY DEPARTMENTS
TO GET A BETTER SENSE OF HOW WE
CAN HELP IMPROVE -- SO WE DID
LOTS AND LOTS OF FOCUS GROUPS
WITH THESE EMERGENCY
DEPARTMENTS.
CERTAINLY WE FOUND BARRIERS TO
CLINICAL PRACTICE CHANGE,
COMPETING PRIORITIES, LACK OF
EXPERIENCE WITH BUPRENORPHINE.
NONE OF THESE EMERGENCY
DEPARTMENT CLINICIANS HAD
RECEIVED TREATMENT -- OR HAD
RECEIVED TRAINING IN MEDICAL
SCHOOL AND THEIR RESIDENCY, THAT
WAS JUST NOT SOMETHING THAT WAS
PART OF TRAINING AT THE TIME.
AND SO MANY PEOPLE WERE
UNCOMFORTABLE WITH THE PRACTICE
THEY DIDN'T KNOW HOW TO DO.
MANY CLINICIANS WERE NOT SURE
HOW THEY WERE TO EFFECTIVELY
LINK PEOPLE TO TREAT WENT OR
WHAT TREATMENT RESOURCES WERE
AVAILABLE IN THEIR COMMUNITY.
OBVIOUSLY LACK OF AWARENESS THAT
ADDICTION IS A TREATABLE
DISEASE, AND STIGMA WERE
CERTAINLY VERY PERVASIVE
THROUGHOUT THE WORK THAT WE
FOUND.
WE ALSO FOUND -- I -- IDENTIFIED
FACILITATORS.
WE DO KNOW THE TRAINING WORKS
AND WE WERE CERTAINLY ABLE TO
TEACH PEOPLE HOW TO INITIATE
BUPRENORPHINE.
WITH A VARIETY OF
TRAINING PROTOCOLS THAT WERE
IMPLEMENTED.
PROTOCOLS PROBABLY THE MOST
IMPORTANT THING TO HELP
IMPLEMENT PRACTICE CHANGE IN
THESE EDs, SO PROTOCOLS
REPRESENT A NUMBER OF REALLY
IMPORTANT THINGS.
ONE, TO HAVE A PROTOCOL, YOU
HAVE LEADERSHIP BUY-IN OR
SUPPORT SO IT INDICATES THAT.
TWO, IT TELLS YOU WHAT TO DO.
SO AS FAR AS QUESTIONS ABOUT IS
THIS THE RIGHT DOSING OR -- IT'S
ALL SORT OF LAID OUT ON THE
PROTOCOL.
AND THREE, IT SETS THE STAGE TO
SAY THAT THIS IS LIKE THE
NORMALIZED CARE WE EXPECT FOR
OUR EMERGENCY DEPARTMENT.
MANY CLINICIANS WERE WORRIED
ABOUT BEING SORT OF ON THE
LEADING EDGE, TO BE THE FIRST
PEOPLE TO DO THAT IN THEIR
EMERGENCY DEPARTMENT, AND
PROTOCOLS SAY THIS IS WHAT WE DO
AND THIS IS PART OF THE PRACTICE
THAT WE HAVE.
TARGETED FEEDBACK TO ED STAFF IS
REALLY IMPORTANT.
ED CLINICIANS SEE PEOPLE WHEN
THEY'RE DOING POORLY.
WE DON'T SEE PEOPLE WHO GO TO
TREATMENT, ARE DOING GREAT, THEY
DON'T COME BACK TO THE ED, WHICH
IS WONDERFUL, BUT IF YOU'RE ABLE
TO ACTUALLY PROVIDE FEEDBACK TO
THOSE CLINICIANS, WHO SAW
PATIENTS, SAY REMEMBER THAT
PATIENT YOU SAW LAST WEEK OR
LAST MONTH, YOU KNOW, THEY'RE IN
TREATMENT AND DOING REALLY WELL.
AND ALL OF THIS IS ABOUT
CHANGING CULTURE.
AND SO I THINK PART OF THIS IS
ABOUT HOW YOU MAKE IT CLEAR THIS
IS PART OF A AN EXPECTATION OF
YOUR CLINICAL PRACTICE.
ONE OF THE FOCUS GROUPS IN A
RURAL SITE IN NE NEW HAMPSHIRE,E
ED DOC I WAS TALKING TO, THAT
STUDY WAS DONE AT YALE, I'M NOT
SURE IT APPLIES TO ME, WHAT I
REALLY WANT TO SEE IS I WANT TO
SEE SOMETHING FROM MY
PROFESSIONAL SOCIETY THAT SAYS
THIS IS ACTUALLY SOMETHING THAT
IS MY JOB, BECAUSE I'M ACTUALLY
REALLY NOT SURE THAT IT IS.
SO ONE OF THE THINGS THAT SORT
OF CAME DIRECTLY OUT OF THIS
RESEARCH WAS A GROUP OF US MET
WITH OUR -- THROUGH THE AMERICAN
COLLEGE OF EMERGENCY PHYSICIANS
WITH THEIR PROFESSIONAL SOCIETY
AND DEVELOPED CONSENSUS
GUIDELINES ON TREATING OPIOID
USE DISORDER IN THE EMERGENCY
DEPARTMENT AND SAID YOU KNOW
WHAT, THIS REALLY IS OUR JOB, WE
CAN DO IT, THIS IS SOMETHING
THAT REALLY IS -- SHOULD BE
CONSIDERED THE STANDARD OF CARE.
AND SO THAT IS OUT THERE AND
THAT IS AVAILABLE.
IF YOU HAVE EDs THAT YOU WORK
WITH WHO THINK IT'S NOT THEIR
JOB, IT IS.
SO FALLING BACK TO ED CONNECT,
WHICH IS THE IMPLEMENTATION
STUDY, AND THE HIGH NEED/LOW
ACCESS EDs.
SO WE DID IMPLEMENTATION WITH
THE STAFF AND WE ALSO DID
PATIENT LEVEL DATA.
AND SO WHEN WE STARTED IN 2018,
THERE WERE NO -- NO ONE.
NONE OF THE SITES WERE
IMPLEMENTING ED INITIATED
BUPRENORPHINE.
SO AFTER A SIX-MONTH FAIRLY
INTENSIVE IMPLEMENTATION
FACILITATION EXPERIENCE, WE
COLLECTED BASELINE LEVEL DATA
AND FOUND THAT JUST OVER SIX
EDs PER -- SIX PATIENTS PER ED
PER MONTH WERE RECEIVING
ED-INITIATED BUPRENORPHINE.
SO NOT A HUGE NUMBER BUT
DEFINITELY A HUGE INCREASE,
CONSIDERING A SIX-MONTH
IMPLEMENTATION PERIOD IN SITES
THAT WERE NOT TOTAL LEISURE THAT
THEY WANTED TO TALK TO US WHEN
WE SHOWED UP THERE.
WE WERE ACTUALLY VERY PLEASED
WITH THAT.
HEAL WAS KIND ENOUGH TO SUPPORT
A SUSTAINABILITY EVALUATION
BECAUSE WE KNOW THAT'S ONE OF
THE MOST IMPORTANT THINGS ABOUT
IMPLEMENTATION RESEARCH, IS DOES
IT CONTINUE.
SO WITHOUT THE IMPLEMENTATION
FACILITATION JUST WANTED TO SEE
WHAT WOULD HAPPEN DOWN THE LINE.
CLEARLY LOTS OF THINGS HAPPENED
IN 2020 AND 2021 AROUND ACCESS
TO ED-INITIATED -- TO OUD CARE,
BUT EVEN WITHOUT ADDITIONAL IF,
WE ACTUALLY SAW A SIGNIFICANT
INCREASE IN THE NUMBER OF
PATIENTS WHO WERE RECEIVING ED
INITIATED BUPRENORPHINE THERE.
SO WE KNOW THAT WE CAN TEACH
CLINICIANS HOW TO DO IT.
WE ALSO WERE TRYING TO DO THESE
TWO THINGS AT ONE TIME, TRYING
TO FIGURE OUT EXACTLY WHAT THE
RIGHT THING IS TO DO.
SO THERE'S STILL LOTS OF WAYS,
LOTS OF QUESTIONS AROUND HOW YOU
ACTUALLY INITIATE BUPRENORPHINE.
STANDARD DOSING, INITIAL STUDY,
WHAT MANY PEOPLE WERE INITIALLY
DOING IN THE EMERGENCY
DEPARTMENT WAS 8 MILLIGRAMS.
THERE'S ALSO HIGH DOSE DURING
THE ED STAY THAT HAS BEEN
LARGELY PIONEERED OUT IN
CALIFORNIA BRIDGE, RATIONALE FOR
THAT IS THAT IT GETS PEOPLE --
IT JUST GETS MEDICATION ON THE
RECEPTORS MORE QUICKLY, GETS
CRAVING AND WITHDRAWAL SYMPTOMS
CONTROLLED MORE QUICKLY.
AND THEN INJECTABLE FORMULATIONS
IS ANOTHER INTERESTING THING TO
THINK ABOUT.
THERE ARE 7 AND 30-DAY
FORMULATIONS BUT IF YOU CAN
ACTUALLY THINK ABOUT GIVING
MEDICATION -- ADMINISTER
MEDICATION TO A PERSON THAT
LASTS FOR A WEEK, SO THEY DON'T
HAVE THE BURDEN OF MISSING A
RIDE TO THE PHARMACY OR NOT
HAVING THEIR INSURANCE CARD OR
THEIR I.D., THINKING ABOUT
DIFFERENT STRATEGIES TO HELP
INCREASE LIKELIHOOD TO LINKAGE
TO TREATMENT.
THIS IS A STUDY THAT WE'RE
CONDUCTING RIGHT NOW.
IT'S ED INNOVATION.
IT IS A CLINICAL TRIAL COMPARING
7-DAY INJECTABLE VERSUS
SUBLINGUAL IN 30 EDs AROUND
THE U.S.
REALLY THE GOAL OF THIS STUDY IS
TO SEE IF ONE OF THESE PERFORMS
BETTER AT LINKING PEOPLE TO
TREATMENT AT 7 DAYS.
LOTS AND LOTS OF PEOPLE INVOLVED
IN THIS AS I SAID, 30 EDs.
WE'RE NOT -- I THINK WE FINISHED
ENROLLMENT THIS SUMMER, WE'RE
VERY, VERY CLOSE BUT I THINK THE
OTHER COOL THING ABOUT IT IS
MANY OF THESE 30 EDs THAT ARE
ENROLLING WERE NOT DOING ED
INITIATED BUPRENORPHINE BEFORE
THIS TRIAL.
SO MOVING FORWARD, THERE ARE
SORT OF TWO STUDIES THAT WE'RE
IN THE PROCESS OF LAUNCHING.
ONE IS AS I ALLUDED TO SORT OF
THE ROLE OF HIGH DOSE
BUPRENORPHINE, WE DON'T KNOW
PROSPECTIVELY WHETHER 8 VERSUS
24 MILLIGRAMS WOULD BE BETTER,
SO WE'RE CURRENTLY IN THE
PROCESS OF LAUNCHING THAT.
PROBABLY LATE THIS SUMMER AGAIN
THROUGH THE HEAL INITIATIVE AND
THE CLINICAL TRIALS NETWORK.
THEN THE LAST THING THAT I
WANTED TO TALK ABOUT IS
SOMETHING THAT IS LIKE A TOTAL
PIVOT BUT ALSO STILL VERY MUCH A
DIFFERENT WAY TO PROMOTE
CLINICAL PRACTICE CHANGE, WHICH
IS REALLY RELYING ON DATA AROUND
HOW YOU CAN INFLUENCE SORT OF
HEALTHCARE INFRASTRUCTURE.
SO PREVIOUS TO THIS GRANT, WE
HAD SORT OF DEVELOPED ED OUD
QUALITY MEASURES BASED ON DO
PEOPLE RECEIVE BUPRENORPHINE IN
THE EMERGENCY DEPARTMENT, DO
THEY RECEIVE A PRESCRIPTION, DO
THEY GET NALOXONE.
SO WE ARE ACTUALLY GOING TO
IMPLEMENT THOSE QUALITY MEASURES
INTO AN EXISTING EMERGENCY
DEPARTMENT CLINICAL DATA
REGISTRY THROUGH THE AMERICAN
COLLEGE OF EMERGENCY PHYSICIANS.
AND SO WE'RE GOING TO AUTOMATE
DATA EXTRACTION AND PERSONALIZE
OU D-DAY TA DASHBOARDS FOR 40
EDs AND DEVELOP A PUBLIC
FACING DASHBOARD.
I'M DEEPLY GRATEFUL TO BE HERE
TODAY AND CLEARLY MY AMAZING
COLLABORATORS ARE THE ONLY
REASON I'M HERE ON THE STAGE
TODAY, SO THANK YOU VERY MUCH.
>> THANK YOU, DR. HAWK.
WE HAVE DR. DEANNA WILSON OF THE
UNIVERSITY OF PENNSYLVANIA.
>> GOOD AFTERNOON, EVERYBODY.
ONE QUICK SECOND.
I THINK WE'RE JUST WAITING FOR
THE SLIDES TO LOAD.
ONE SECOND.
I WANTED TO THANK THE HEAL
PROGRAM FOR THIS AWARD AND THE
OPPORTUNITY TO SHARE THESE
FINDINGS WITH ALL OF YOU.
I HAVE NO CONFLICTS TO DISCLOSE
BUT I JUST WANTED TO OFFER A
NOTE ON LANGUAGE.
BECAUSE OF THE IMPORTANCE OF
HEARING PEOPLE THROUGH THEIR OWN
WORDS, I WANT TO NOTE THAT I'LL
REPORT PARTICIPANT QUOTATIONS
VERBATIM, EVEN THOUGH SOME OF
THE LANGUAGE YOU'LL HEAR MAY BE
NEGATIVE AND TROUBLING.
STIGMA IS A SOCIAL PROCESS BY
WHICH INDIVIDUALS ARE LABELED,
STEREOTYPED AND MARGINALIZED ON
THE BASIS OF REAL OR PERCEIVED
STATUS OR ATTRIBUTES.
STIGMA TOWARDS PATIENTS WITH
BOTH PAIN AND OPIATE USE
DISORDER REPRESENTS AN URGENT
PUBLIC HEALTH PROBLEM.
WE KNOW THAT NEARLY HALF OF
PATIENTS WHO INJECT DRUGS,
PARTICULARLY OPIOIDS, REPORT
HAVING CHRONIC PAIN.
AND WE KNOW THAT STIGMA IMPACTS
THE QUALITY OF CARE THAT THOSE
PATIENTS RECEIVE.
BOTH IN THE UNDERTREATING AND
UNDERASSESSING OF PAIN LEADING
TO DISENGAGEMENT FROM TREATMENT
AND CARE, AND ULTIMATELY POOR
CLINICAL OUTCOMES.
AND SO OUR STUDY ASKS, HOW DOES
STIGMA IMPACT HOSPITALIZED
PATIENT WHO HAVE BOTH OPIATE USE
DISORDER AND ACUTE AND CHRONIC
PAIN, WITH THE ULTIMATE GOAL OF
LEARNING HOW WE CAN REDUCE
STIGMA IN THE HOSPITAL SETTING
AND IMPROVE OUTCOMES FOR THIS
PATIENT POPULATION.
IN ORDER TO ANSWER THESE
QUESTIONS, WE'RE RELYING ON
HUMAN CENTERED DESIGN.
SO THIS DRAWS ON THE FIELDS OF
TECHNOLOGY AND DESIGN THINKING.
IT ALLOWS US TO UNDERSTAND THE
NEEDS AND DESIRES OF PEOPLE MOST
IMPACTED BY A PROBLEM.
AND THROUGH A SERIES OF
PARTICIPATORY ACTIVITIES, IT
ALLOWS FOR INTERVENTIONS TO BE
CO-CREATED WITH END USERS, WHICH
IN THIS CASE ARE PEOPLE WHO HAVE
BOTH PAIN AND OPIATE USE
DISORDER.
MOST IMPORTANTLY, IT ALLOWS US
TO AUTHENTICALLY ENGAGE PEOPLE
WITH LIVED EXPERIENCE,
RECOGNIZING THEIR EXPERIENCE AS
ITS OWN VALID TRUTH, AND TO DO
RESEARCH THAT IS WITH
MARGINALIZED POPULATIONS.
THE FRAMEWORK WE'RE USING IS A
DESIGN SPRINT, 8 TO 12 PEOPLE
WITH LIVED EXPERIENCE AT A TIME
OVER THE COURSE OF FIVE SESSIONS
AND A SERIES OF TARGETED HUMAN
CENTERED DESIGN ACTIVITIES.
THAT MOVES PARTICIPANTS FROM
MAPPING OR DEFINING A PROBLEM
TOGETHER TO CREATING
INTERVENTION COMPONENTS
TOGETHER, PROTOTYPING, AND THEN
TESTING THEM WITH PROVIDERS AND
PATIENTS.
THE FIRST STEP OF THE DESIGN
PROCESS REQUIRES US TO MAP THE
PROBLEM OF STIGMA IN THE
HEALTHCARE SETTING WITH
PARTICIPANTS.
IN ANTICIPATION OF THIS FIRST
STEP, WE'VE CONDUCTED
QUALITATIVE SEMI STRUCTURED
INTERVIEWS TO CAPTURE A RANGE OF
PERSPECTIVES THAT WILL SHARE AT
OUR FIRST DESIGN SPRINT SESSION.
FOR THE REMINDER OF MY TIME
TODAY, I'LL BE DISCUSSING THOSE
FINDINGS.
WE'VE ASKED HOW IS STIGMA IN
HOSPITALHOSPITALIZED PATIENTED
MANIFESTED?
WHAT ARE THE BEST PRACTICES IN
THE HOSPITAL SETTING AND WHAT
ARE SOME OPPORTUNITIES AND
CHALLENGES.
WE'VE INTERVIEWED HOSPITALIZED
PATIENTS WITH BOTH OPIOID USE
DISORDER AND CHRONIC PAIN WHO
ARE ENGLISH SPEAKING AND OVER
THE AGE OF 18.
WE INTERVIEWED PROVIDERS WHO
CARED FOR PATIENTS, HOSPITALIZED
WITH CHRONIC PAIN AND OUD WITHIN
THE PAST YEAR, AND WE
INTERVIEWED SUFFICIENT
PARTICIPANTS IN EACH GROUP TO
ACHIEVE SATURATION.
WE INTERVIEWED A TOTAL OF
21 PATIENTS AGES 24 TO 62 YEARS
OF AGE, A FIFTH OF WHOM WERE
BLACK AND HALF WHO WERE FEMALE.
WE INTERVIEWED 16 PROVIDERS, THE
BULK OF WHOM WERE WHITE, AND
HALF OF WHOM WERE FEMALE.
INTERVIEWS WERE 25 TO 60 MINUTES
IN LENGTH, AUDIO RECORDED,
TRANSCRIBED, AND THEN WE
ANALYZED THEM USING THEMATIC AND
CONTENT ANALYSIS GUIDED BY THE
HEALTH STIGMA FRAMEWORK.
KEY FINDINGS WITH STIGMA WAS
COMMON, INTERSECTIONAL BOTH BY
THE CONDITION, ACE, RAGE AND
GENDER.
MANAGING CARE FOR PATIENTS WHO
HAVE BOTH OPIATE USE DISORDER
AND PAIN IN THE HOSPITAL SETTING
WAS COMPLEX AND PARTICULARLY
CHALLENGING FOR PROVIDERS.
AND STIGMA NEGATIVELY IMPACTS
THE QUALITY OF CARE PATIENTS
WITH OUD AND PAIN RECEIVED IN
THE HOSPITAL SETTING.
THIS SCHEMATIC ADAPTED FROM THE
FRAMEWORK ILLUSTRATES SOME OF
THE KEY RELATIONSHIPS WE FOUND
IN OUR INTERVIEWS.
DRIVERS OF STIGMA LIKE PROVIDERS
FEARING THE WORSENING OF
ADDICTION BY GIVING PATIENTS IN
PAIN OPIOIDS, JUDGMENT ABOUT
PEOPLE WHO USE DRUGS, NEGATIVE
STEREOTYPES AND PREJUDICE ABOUT
ADDICTION COUPLED WITH A LACK OF
AWARENESS BY PROVIDERS OF THEIR
OWN PERSONAL BIASES, AND HOW
THAT MIGHT BE CONTRIBUTING TO
NEGATIVE CLINICAL CARE.
THESE MARK PEOPLE WITH OPIATE
USE DISORDER WITH PAIN IN OFTEN
STIGMATIZING WAY, FOR EXAMPLE IN
LANGUAGE IN THE ELECTRONIC
HEALTH RECORD.
THESE THEN LEAD TO STIGMA
PRACTICES, LIKE STEREOTYPING AND
DISCRIMINATORY EXPERIENCES, LIKE
INTERNALIZED STIGMA THAT
PATIENTS DESCRIBE DIRECTING
TOWARD THEMSELVES AND STIGMA
THAT THEY BOTH EXPERIENCE OR
ANTICIPATE EXPERIENCING.
THESE FEEDBACK TO DRIVE
ADDITIONAL STIGMATIZING
BEHAVIORS EVENTUALLY LEADING TO
POOR CLINICAL OUTCOMES.
ONE OF THE MOST SIGNIFICANT POOR
OUTCOMES WAS A RETURN TO
SUBSTANCE USE OR AN INCREASE IN
SUBSTANCE USE DRIVEN BY POOR
LEHMANALYMANAGED PAIN, SOMETHINW
NOT ALL PATIENTS WILL SURVIVE.
THIS WOMAN DESCRIBED HER HUSBAND
IN REMISSION FOR OPEN YAID USE
DISORDER, HAD SPINAL SURGERY
THEN SENT HOME.
THEY SENT HIM HOME IN A WEEK
WITH FOUR OXYCODONES AND MO TRIN
AND HE KEPT COMING BACK, WE KEPT
COMING BACK.
HE SAID I CAN'T TAKE THE PAIN.
THEY COULD HAVE GAVE HIM
VICODIN, THEY COULD HAVE GIVEN
HIM IG HE COULDN'T TAKE THE PAIN
SO WHAT DEWE DO?
HE WENT TO THE STREET AND IT
KILLED HIM INSTANTLY.
IT WASN'T LIKE HE WANTED TO GET
HIGH, HE JUST COULDN'T STAND THE
PAIN.
NEGATIVE STEREOTYPES AND
PREJUDICE WERE COMMON THROUGHOUT
THE HEALTHCARE SYSTEM.
PEOPLE WHO USE DRUGS WERE
DESCRIBED IN OFTEN NEGATIVE
WAYS.
A PROVIDER SAYS I CAN'T EVEN
REALLY IMAGINE HOW ANYBODY COULD
DO THAT TO THEMSELVES.
IT'S CLEARLY A TERRIBLE PRACTICE
SO DESTRUCTIVE AND DANGEROUS.
PEOPLE WHO INJECTED DRUGS WERE
VIEWED EVEN MORE NEGATIVELY.
PROVIDER SAYS THE WORD DIRTY
COMES TO MIND.
I DON'T KNOW IF THAT'S ME OR
EVERYBODY, I DON'T REALLY THINK
PEOPLE ARE DIRTY, BUT IT'S SORT
OF MORE LIKE THE JUNKIE HANGING
OUT ON SCID ROW. ON SKID ROW.
A PROVIDER SAYS PATIENTS ARE
WEAK, BROKEN, IT COMES FROM
SOMETHING ABOUT THEIR MORAL
FIBER OR CHARACTER THAT'S
PREDISPOSED THEM TO THIS
CONDITION.
DISCRIMINATORY ATTITUDES WERE
COMMON.
A PROVIDER SAID PEOPLE THAT USE
SUBSTANCES DON'T NECESSARILY
DESERVE THE TYPE OF CARE OTHER
PEOPLE SHOULD.
ANOTHER DESCRIBES PEOPLE WITH
OPIATE USE DISORDER AS BROKEN
PEOPLE, BROKEN BEYOND REPAIR,
AND THAT THEY'RE NOT GOING TO
GET BETTER.
ADDITIONALLY, PATIENTS DESCRIBE
BEING BLAMED FOR THEIR PAIN IF
IT WAS THE RESULT OF INJECTION
DRUG USE OR OTHER SUBSTANCE USE.
PROVIDERS OFTEN HAVE SEEN THE
WORST IF A PATIENT HAD A HISTORY
OF ADDICTION AND PATIENTS
DESCRIBED OFTEN BEING REMOVED
FROM PRACTICES, CUT OFF FROM
PRESCRIPTIONS AND FORCED TO
EXPERIENCE WITHDRAWAL.
THERE'S INTERSECTIONAL STIGMA SO
STIGMA BOTH FOR PATIENT WITH
PAIN AND STIGMA WITH OPIATE USE
DISORDER, THESE PATIENTS ARE
VIEWED AS DRUG SEEKING, BOTH
PATIENTS AND PROVIDERS ENDORSED
THIS.
PATIENTS DESCRIBED A HOST OF
EXPERIENCED STIGMA WITH POOR OR
SUBSTANDARD CARE THEY RELATED AS
BEING A RESULT OF THEIR
ADDICTION, LESS FREQUENT
CHECK-INS AND SUPPORTS FROM ALL
MEMBERS OF THE HEALTHCARE TEAM,
FROM ATTENDING PHYSICIANS, TO
BEDSIDE NURSES AND OFTEN POORLY
MANAGED PAIN.
THIS DESCRIBES AN EXPERIENCE
WHERE A PROVIDER WAS FIXING HER
FOOT AND SHE SAYS HE LITERALLY
CUT IN THE WRONG SMOT AND MADE A
COMMENT LIKE OH, WELL, YOU'LL
JUST NOD OUT SOON SO I CAN HIT
THE RIGHT SPOT.
STIGMA WAS INTERSECTIONAL WITH
BLACK -- WERE VIEWED MORE
NEGATIVELY.
"I DO THINK SOMETIMES
INDIVIDUALS THAT ARE NON-WHITE
BACKGROUND DO HAVE POTENTIAL
STIGMA FOR INCREASED DRUG
SEEKING BEHAVIORS."
ANOTHER SAYS, BLACK PEOPLE WERE
VIEWED AS BEING ESPECIALLY
DEMANDING IN THEIR PAIN NEEDS,
AND AT HIGH RISK OF WORSENING
THEIR OPIATE USE DISORDER.
A PATIENT WHO IDENTIFIED AS
BLACK SAYS, IN HIS EXPERIENCE,
BLACKS ARE SEEN AS DEPENDENT,
LAZY, GREEDY, AS HEARTIER STOCK
LIKE CATTLE AND ABLE TO ENDURE
MORE PAIN, OR SIMPLY THEY JUST
DON'T CARE AND WE HAVE TO ENDURE
MORE PAIN.
IT'S DISHEARTENING, HUMILIATING,
DEGRADING, SUBJUGATING.
PROVIDERS DESCRIBE A STRUGGLE
AND NEED FOR CLINICAL EQUIPOISE
AROUND MANAGING PAIN AND OPIATES
WHO OFTEN -- WITH OPIOIDS AND
PATIENT WHO ARE OFTEN HIGHLY
OPIATE-TOLL RAPT AND DEPENDENT
ON FENTANYL.
THEY RECOGNIZE THE HIGH OPIATE
NEEDS OR PATIENTS USING FENTANYL
AND NEED TO USE MORE POTENT HIGH
DOSE FOR PAIN CONTROL, YET FEAR
THE BALANCE OF GIVING OPIOIDS
FOR ACUTE PAIN, FEARS OF CAUSING
EEUPHORIA WITH USE OF HIGH DOSE
OPIOIDS AND THE PERCEIVED NEED
TO GIVE DOSES FAR ABOVE THEIR
COMFORT ZONE.
PARTICIPANTS IDENTIFIED SOME
STRATEGIES TO MITIGATE STIGMA
SUCH AS PRIORITIZING PATIENT
GOALS LIKE USING LESS SUBSTANCES
OVER PROVIDER PREFERENCES LIKE
TOTAL ABSTINENCE.
UTILIZING PATIENT-CENTERED
INTERVIEWING STRATEGIES TO
ESTABLISH RAPPORT AND FACILITATE
HONEST COMMUNICATION BETWEEN
PROVIDERS AND PATIENTS,
RECOGNIZING THE REAL IMPACT OF
TRAUMA AND MENTAL HEALTH AND
PEOPLE'S EXPERIENCE OF PAIN, AND
HOW THEY MIGHT ACT OR RESPOND IN
THE HEALTH SETTING.
AND ENCOURAGING PROVIDERS TO DO
THEIR OWN WORK REFLECTING ON
THEIR OWN BIASES TO REDUCE THE
LIKELY IMPACT OF THOSE BIASES IN
DRIVING CLINICAL
DECISION-MAKING.
USING ROLE MODELS OR CHAMPIONS
TO CHALLENGE NEGATIVE VIEWS OF
PATIENTS WITH OUD AND
DEMONSTRATE BEST PRACTICES.
FOR PAIN MANAGEMENT
SPECIFICALLY, PROVIDERS
RECOMMENDED USING HIGHER
QUANTITIES OF SHORT ACTING
OPIOIDS AND USING PROTOCOLS TO
HELP ADEQUATELY AND AGGRESSIVELY
MANAGE PAIN, DEMONSTRATING
PATIENTS THAT THEIR BELIEFS
ABOUT PAIN ARE BOTH HEARD AND
BELIEVED.
RECOGNIZING THAT BUPRENORPHINE
ALONE IS HELPFUL BUT NOT
SUFFICIENT.
THEY FOUND IT HELPFUL TO SET
CLEAR GOALS FOR ANALGESIA AND AT
DISCHARGE THAT NEEDED SUPPORT
AND TAPERING OR DE-ESCALATING
OPIOIDS, AND BOTH PATIENTS AND
PROVIDERS FOUND IT HELPFUL TO
WORK WITH SPECIALTY PAIN OR
ADDICTION MEDICINE TEAMS IN THE
HOSPITAL SETTING.
SO WHERE DO WE GO FROM HERE?
WE'RE PRESENTING THESE FINDINGS
TO PATIENTS WITH LIVED
EXPERIENCE AS PART OF THE
REMAINDER OF THE PROCESS AND
WE'LL USE THIS AS A JUMPING OFF
POINT TO CODESIGN TOGETHER
ULTIMATELY A MULTILEVEL STIGMA
INTERVENTION TO BE DEPLOYED IN
THE HOSPITAL SETTING.
AND A WAY THAT REALLY CENTERS
THE VOICES, PERSPECTIVES AND
DESIRES OF PEOPLE WITH LIVED
EXPERIENCE WITH AN EMPHASIS ON
SORT OF CENTERING EQUITY FOR
THOSE IMPACTED BY OVERLAPPING
AND COMPOUNDING SYSTEMS OF
DISADVANTAGE AND BIAS.
THANK YOU.
>> THANK YOU, DR. WILSON.
AND I'LL SAY THAT THESE
INVESTIGATORS ARE TRAILBLAZERS
NOT BECAUSE OF THE INNOVATIVE
RESEARCH THAT THEY'RE PRESENTING
HERE BUT ALSO BECAUSE THEY
COMPLETED THEIR PRESENTATIONS
WITH FIVE MINUTES TO SPARE.
SO I THINK WE HAVE TIME FOR A
QUESTION OR TWO, SO IF ANYBODY
IN THE AUDIENCE HAS A BURNING
QUESTION, PLEASE FEEL FREE TO
COME UP TO ONE OF THE MICS.
WE'VE GOT ONE HERE, GREAT.
>> MIC ON?
OKAY, GOOD.
THE INVESTIGATOR, I BELIEVE,
FROM THE UNIVERSITY OF
PENNSYLVANIA, YES, THANK YOU
VERY, VERY MUCH FOR PRESENTING
THAT INFORMATION, SPECIFICALLY
ON STIGMA.
ALLOW ME TO INTRODUCE MYSELF.
MY NAME IS RAY LEI, FORMERLY
HOMELESS, HON RAB BLI DISCHARGED
UNITED STATES MARINE LIVING WITH
A DUAL DIAGNOSIS.
OF SCHIZO EFFECTIVE DISORDER AND
POLYSUBSTANCE ABUSE ISSUES.
I AM A PERSON THAT HAD MY FIRST
TASTE OF HEROIN WHEN I WAS IN
HONG KONG.
AND I HAVE ACTUALLY HAD COCAINE
IN THE JUNGLES OF COLOMBIA.
MA'AM, WHEN YOU TALKED ABOUT
STIGMA, I WENT THROUGH A PROCESS
OF ALMOST 14 YEARS FOR SERVICE
CONNECTION FOR MY MENTAL HEALTH
AND SUBSTANCE USE ISSUES.
AND THE FINDINGS THAT YOU JUST
PRESENTED ARE, FOR LACK OF A
BETTER WAY TO PUT IT, TRUE.
BUT I HAVE TO STATE, I WOULD
LOVE TO BE PART OF YOUR STIGMA
REDUCTION PROGRAM.
I WAS -- I STATE THAT FOR THE
SIMPLE REASON, I SPENT OVER 10
YEARS HOMELESS.
I HAVE LIVED WITH SCHIZOPHRENIA
FOR OVER 60 YEARS.
OKAY?
AND TODAY, I AM A HOMEOWNER, I
AM A BUSINESS OWNER.
I'M ALMOST 17 YEARS CLEAN AND
SOBER.
OKAY?
I AM A MEMBER OF THE BOARD OF
DIRECTORS WITH THE NATIONAL
ALLIANCE ON MENTAL ILLNESS FOR
BOTH THE STATE OF INDIANA AND
THE NATION.
AND SO I BELIEVE IN BUSTING THAT
STIGMA TREMENDOUSLY.
I'M A PEER SUPPORT SPECIALIST, A
VETERANS' ADMINISTRATION PEER
SUPPORT SPECIALIST AND ALSO FOR
THE STATE OF INDIANA AND A
TRAINER OF SUCH.
AND SO I DO KNOW THAT WE HAVE
QUITE A FEW CREDENTIALED PERSONS
IN THIS AUDIENCE.
BUT I STILL -- I SAY AGAIN, I
WANT TO MAKE SURE THAT HOPEFULLY
WE CAN FIGURE OUT A WAY THAT I
CAN BE PART OF YOUR STIGMA
BUSTING CAMPAIGN.
>> THANK YOU SO MUCH.
THANK YOU FOR YOUR STORY, AND
YOUR SERVICE.
I MEAN, I WOULD LOVE TO CONNECT
WITH YOU AFTER.
I THINK WHAT YOU'RE -- HOW
THE -- LISTENING TO THESE QUOTES
SORT OF MAKE YOU FEEL IS
SOMETHING THAT IS REALLY COMMON
WHEN I SHARE THESE FINDINGS WITH
OTHER FOLKS LIVING WITH PAIN AND
OPIOID USE DISORDER.
I THINK OUR PATIENTS -- I'M A
PHYSICIAN AND MY PATIENTS
DESCRIBE THIS TO ME ALL THE
TIME, AND I THINK IT'S SOMETIMES
REALLY SHOCKING TO SEE KIND OF
BLOWN UP ON A SCREEN, BUT THIS S
IS WHAT PEOPLE ARE LIVING WITH
EVERY DAY.
STIGMA IS ALIVE AND REAL IN OUR
HEALTH SYSTEM.
I THINK WE NEED ALL PEOPLE TO
TAKE UP ADDRESSING STIGMA IN
WHATEVER KIND OF WORK THEY DO.
SO THANK YOU SO MUCH.
>> WITH PLEASURE.
AND I WOULD JUST LIKE TO ADD
THAT WHAT YOU JUST STATED RIGHT
THEN IS ALSO SO, SO, SO, SO
TRUE.
BUT I DO HAVE SOME OF MY
BUSINESS CARDS AND NAMI CARDS
WITH ME, AND I WILL BE GLAD TO
WALK DOWN AND GIVE YOU ONE.
>> THANK YOU SO MUCH.
I THINK WE'VE GOT TWO MINUTE
LEFT SO ONE MORE QUESTION.
WE'VE GOT SOMEONE AT THE MIC AND
THEN WE'LL TRANSITION.
>> MY QUESTION WAS FOR DR. HAWK.
I'M ALSO A LIVED EXPERIENCE
HEROIN ADDICT AND COCAINE.
I MEAN, HONESTLY, EVERYTHING.
THOSE WERE MY TWO FAVORITES,
THOUGH.
AND MY FIRST JOB AS A PEER
SUPPORT SPECIALIST WAS IN
ST. LOUIS WITH THE EPIC PROGRAM.
HAVE YOU HEARD OF THAT BEFORE?
>> IT DEPENDS ON WHICH ONE.
>> IT'S ENGAGING PATIENTS IN
CONTINUOUS CARE.
SO I WAS AN EPIC COACH FOR ABOUT
FIVE YEARS AND IT'S KIND OF
SIMILAR TO THAT, SO I WAS JUST
WONDERING IF YOU HAD GOTTEN ANY
INFORMATION OR BEEN ABLE TO USE
THEM AT ALL.
>> SO I DON'T KNOW ABOUT THAT
PARTICULAR PROGRAM, BUT MY
SLIDES DID NOT INCLUDE THE
SIMILAR QUOTES, BUT WE KNOW THAT
THE EMERGENCY DEPARTMENT HAS
BEEN A REALLY TRAUMATIC PLACE
FOR PEOPLE WHO USE DRUGS AND WE
ARE TRYING TO DO BETTER.
AND HONESTLY PEER NAVIGATORS,
PEER COACHES ARE A REALLY
IMPORTANT PART OF HELPING TO
CONNECT FOLKS.
>> WE WERE ABLE, LIKE, IF
SOMEBODY PRESENTED WITH A
WITHDRAWAL OR AN OVERDOSE AND
AGREED TO GET HELP, WE HAD AN
HOUR TO GET TO THE EMERGENCY
ROOM, AND WE COULD GET THEM IN
SAME DAY OR NEXT DAY TREATMENT
AND FOLLOW THEM FOR SIX MONTHS.
AND WE WORKED -- THE DOCTORS
WERE VERY OPEN TO IT.
>> ONE THING I WILL SAY ABOUT
NAVIGATOR PROGRAMS THAT GOES
BACK TO THE IDEA OF CULTURE IS
THAT WHEN YOU HAVE PEOPLE WITH
LIVED EXPERIENCE IN YOUR ED, IT
HELPS CLINICIANS LEARN,
UNDERSTAND A LITTLE BIT MORE
ABOUT HOW TRAUMATIC THESE
EXPERIENCES CAN BE FROM
PATIENTS, AND SO THERE'S LIKE A
LITTLE BIT OF SORT OF NAVIGATING
AND TEACHING THAT HAPPENS WITH
THAT.
SO THANK YOU FOR THE WORK THAT
YOU DO AND FOR ALL OF THE PEERS
AND NAVIGATORS THAT HELP OFFSET
WHAT IS VERY CLEARLY A BROKEN
HEALTHCARE SYSTEM TO TRY TO GET
PEOPLE WHAT THEY NEED.
>> I ALSO HAVE MY CARDS AND
WOULD LOVE TO HELP WITH
ANYTHING.
>> ALL RIGHT.
JOIN ME AGAIN IN THANKING ONE
MORE TIME THE TRAILBLAZER
AWARDEES, AND I'M SO GLAD THAT
WE HAD TIME FOR THAT
CONVERSATION.
SO NEXT WE HAVE A PANEL FROM
HEAL CONNECTIONS.
AS A REMINDER, THIS IS AN EFFORT
THAT'S FUNDED BY THE NIH HEAL
INITIATIVE TO TRANSLATE HEAL
RESEARCH INTO ACTION.
AND THE PANEL IS GOING TO BE LED
BY JESSICA HULSEY, THE CEO AND
FOUNDER OF THE ADDICTION POLICY
FORUM.
SO I WANT TO WELCOME JESS AND
THE PANELISTS UP ON THE STAGE.
THANK YOU SO MUCH.
>> ON?
GOOD TO GO.
ALL RIGHT.
SO GREAT TO BE ABLE TO SHARE
SOME OF THE WORK OF HEAL
CONNECTIONS WITH ALL OF THE
TODAY.
MY NAME IS JESSICA HULSEY WITH
THE ADDICTION POLICY FORUM AND
WE'RE REALLY EB SITED TO JOIN
WITH OUR PARTNERS AT GEORGE
MASON UNIVERSITY, DUKE
UNIVERSITY, CHESTNUT HEALTH
SYSTEMS AND SO MANY OTHERS TO
REALLY BRING THIS WORK TOGETHER
ON HEAL CONNECTIONS.
A LITTLE BIT, AND I'M REALLY
EXCITED WE HAVE SOME OF OUR KEY
PARTNERS THAT I COULD HAND THIS
OVER TO TODAY, HEAL CONNECTIONS
IS REALLY HERE TO SERVE ALL OF
YOU.
TO DO A BETTER JOB OF
MEANINGFULLY SHARE YOUR STUDY
FINDINGS AND YOUR WORK WITH THE
BROADER COMMUNITY.
HOW CAN WE
MAKE SURE NEW SCIENCE, NEW
INTERVENTIONS, NEW INNOVATIONS
GET INTO THE HANDS OF THOSE WHO
NEED IT THE MOST, WHO NEED --
ARE WAITING FOR MORE DIRECTION
AND MORE GOOD NEWS, AND THERE'S
SO MUCH THAT'S EXCITING UNDERWAY
FROM HEAL, IT'S REALLY EXCITING
WORK THAT WE GET TO TAKE PART
IN.
A LITTLE BIT MORE ABOUT HEAL
CONNECTIONS AND THE WORK.
AND WE HAVE LOTS OF THE TEAM
HERE THAT WORK ON HEAL
CONNECTIONS FROM ALL THESE
DIFFERENT INSTITUTIONS, SO IF
YOU COULD RAISE YOUR HAND AND
SAY HELLO TO EVERYONE.
IF YOU HAVE PAPERS COMING OUT
SOON, PLEASE CHAT WITH US RIGHT
BEFORE YOU HEAD OUT.
WE HAVE TWO MAIN GOALS THAT
WE'RE WORKING ON.
WE CREATE BIDIRECTIONAL
COMMUNICATION WITH THE LARGER
COMMUNITY, SO THIS ISN'T JUST US
SHARING WITH THE LARGER
COMMUNITY WHAT YOU'RE WORKING
ON, BUT THIS IS ALSO US
PROVIDING NIDA, NIH, NINDS
LEADERSHIP AND OTHERS WITH
UPDATES ON WHAT'S HAPPENING ON
THE GROUND, SO CREATING THESE
FEEDBACK LOOPS SO WE GET
INFORMATION DIRECTLY FROM OUR
COMMUNITIES ON A REGULAR BASIS.
THIS ALSO MEANS WE FOCUS ON
RAPID MEANINGFUL TRANSLATION OF
SCIENCE.
AND WHAT DO WE MEAN BY THAT?
MAKING SURE THAT WE GET
TRANSLATION OF CONTENT CORRECT,
DIFFERENT FIELDS AND AUDIENCES
HAVE DIFFERENT LEARNING
PREFERENCES AND FORMATS, SO WE
MAKE SURE WE GET THAT RIGHT AS
WE SEND YOUR RESEARCH AND YOUR
DATA OUT TO THE WORLD.
WE FOCUS ON KNOWLEDGE
TRANSLATION, WE DO
DISSEMINATION, WE HELP WITH
IMPLEMENTATION.
ALL OF THESE ACTIVITIES ARE
ROLLED UP INTO HEAL CONNECTIONS.
THE ULTIMATE GOAL IS TO HELP
BRIDGE THIS SCIENCE TO PRACTICE
GAP.
IN ORDER TO DO THAT, WE NEED TO
MAKE SURE WE GO BEYOND SHARING
WITH OTHER RESEARCHERS AND
SCIENTISTS, BUT PATIENTS,
INDIVIDUALS WITH LIVED
EXPERIENCE, PRACTITIONERS,
STAKEHOLDERS, COMMUNITY-BASED
ORGANIZATIONS, ADVOCATES.
THE LIST GOES ON.
HOW DO WE BETTER ENGAGE THEM?
IN TERMS OF MEANINGFUL
ENGAGEMENTS, YOU HAVE A SAMPLING
TODAY OF SOME OF OUR AMAZING
ORGANIZATIONS THAT I REALLY
DESCRIBE AS "THE DISSEMINATION
MACHINE" THAT WE'RE CREATING.
WE HAVE MAPPED 30 INITIAL
PRIORITY AUDIENCES TO MAKE SURE
THAT WE ENGAGE ON A MONTHLY
BASIS TO GET ANY NEW KNOWLEDGE
OUT TO THIS COMMUNITY.
SO YOU CAN SEE THIS RANGES FROM
HEALTH, HEALTHCARE PROVIDERS,
POLICY MAKERS ACROSS THE
FEDERAL, STATE, CITY AND COUNTY
LEVELS.
PATIENTS, THOSE WITH LIVED
EXPERIENCE, INCLUDING
PRIORITIZING PRIORITY
POPULATIONS, THAT'S ACTUALLY
WHAT WE PREFER TO BE CALLED, SO
WE ASK AND WE'VE SORT OF EVEN
NAMED OUR COMMITTEES BASED ON
FEEDBACK FROM THE FIELD.
COMMUNITY SERVICES AND EVEN
CRIMINAL JUSTICE ASSOCIATIONS.
HERE INSTEAD OF REINVENTING THE
WHEEL, WE RELY ON THE MEMBERSHIP
AND NATIONAL ASSOCIATIONS THAT
ACTUALLY HAVE THOSE MEMBERS WE
WANT TO ENGAGE.
THESE ARE LARGE ORGANIZATIONS
ACROSS LIVED EXPERIENCE, HEALTH,
COMMUNITY SERVICES, AND
GOVERNMENT THAT ARE PART OF THE
HEAL CONNECTIONS MECHANISM.
A COUPLE KEY COMPONENTS THAT WE
HAVE, AND THEN I CAN SHARE A
LITTLE BIT OF OUR SUCCESSES AND
THE FUN WE'VE HAD IN THE FIRST
YEAR.
WE HAVE A PATIENT AND
STAKEHOLDER DISSEMINATION
NETWORK ALONG WITH OUR NATIONAL
ASSOCIATION PARTNERS, YOU'RE
GOING TO MEET SOME TODAY.
THAT'S OVER 140 ORGANIZATIONS
THAT ARE PART OF HEAL
CONNECTIONS.
THEY MAY NOT BE INTERESTED IN
EVERY SINGLE STUDY THAT COMES
OUT, BUT YOU WOULD BE SURPRISED
ON THE INTEREST AND ENGAGEMENT
THAT WE GET FROM THESE 140
GROUPS.
WE ALSO HAVE VERY IMPORTANTLY 11
LIVED EXPERIENCE PANELS MADE UP
OF OVER 55 INDIVIDUALS WITH
LIVED AND LIVING EXPERIENCE WITH
SUBSTANCE USE DISORDER AND PAPEN
WHO MAKE SURE WE ARE TRANSLATING
AND COMMUNICATING EFFECTIVELY
FOR OUR LIVED EXPERIENCE
COMMUNITY.
THANK YOU.
WE HAVE SOME OF OUR PANEL
MEMBERS IN THE ROOM TODAY.
AND HAVING YOU TAKE PART IN THIS
SCIENTIFIC MEETING AND MEETING
ALL THESE RESEARCHERS AND
INVESTIGATORS, IT'S SUCH AN
IMPORTANT MOMENT TO MAKE SURE
THAT WE ARE ENGAGING, THAT WE'RE
COMMUNICATING EFFECTIVELY TO ALL
WHO ARE IMPACTED BY HEAL
RESEARCH, AND WE'RE SO GLAD THAT
YOU'RE HERE WITH US.
THE OTHER PIECE THAT WE HAVE IS
RAPID FEEDBACK TEAMS.
WE HAVE SET UP THESE TEAMS THAT
PROVIDE SAME-DAY INPUT ON OUR
CONTENT THAT WE DEVELOP.
IF YOU WANT A PARTICULAR PIECE
OF INFORMATION TO GO OUT TO
EMERGENCY DEPARTMENTS, THEN WE
CAN MAKE SURE THAT THE AUDIENCE
MIGHT INCLUDE THOSE PHYSICIANS
AND NURSES BUT IT COULD INCLUDE
PEERS, PEER RECOVERY SUPPORT, IT
CAN INCLUDE PATIENTS THEMSELVES,
AND WE CAN PROVIDE SAME-DAY OR
VERY QUICK TURNAROUND TO MAKE
SURE WE GET THOSE PRODUCTS
CORRECT.
SO WHAT HAVE WE BEEN DOING
RECENTLY?
JUST A COUPLE EXAMPLES OF OUR
WORK.
THREE REALLY FUN PROJECTS.
ONE TRANSLATING AND
DISSEMINATING EAT, SLEEP,
CONSOLE.
PUSHING OUT THE PAIN AND NEURAL
BIOMARKERS PAPER AND STUDY OUT
OF THE BRAIN INITIATIVE.
AND SHARING THE OPIOID-OVERDOSE
REDUCTION CONTINUUM OF CARE
APPROACH, OORCCA, OUT OF THE
CASE STUDY.
SO THESE ARE THREE CASE STUDIES
WE'VE HAD IN THE FIRST YEAR OF
OPERATING THIS CENTER.
SO WHAT WAS SORT OF INVOLVED IN
THIS TRANSLATION PIECE?
SO I LOVE ALL Y'ALL, BUT NOT
MOST OF THE COMMUNITY READS
THOSE BIG PAPERS YOU ALL
PUBLISH.
IT IS SUCH GREAT SCIENCE AND
WORK, HOWEVER, WE HAVE LEARNED
FROM DOING INTERVIEWS WITH OUR
KEY AUDIENCES THAT NOT --
THERE'S A HIGH NEED FOR
TRANSLATING INTO FORMATS THAT
MAKE SENSE TO THOSE ON THE
GROUND.
THOSE INCLUDE BLOG POSTS,
ONE-PAGE SUMMARIES, NEWSLETTER
ARTICLES, INFO GRAPHICS, SOCIAL
MEDIA GRAPHICS, KEY TAKEAWAYS
EMAILS, INSTEAD OF ASSUMING THAT
WE KNOW HOW YOU WANT YOUR
INFORMATION, WE ASK OUR GROUPS
AND THEN WE TAKE ORDERS AND PUSH
OUT THE CONTENT THAT WORKS BEST
FOR THEM.
SO HERE'S AN EXAMPLE WE HAD OVER
15 DIFFERENT PRODUCTS THAT WE
PUSHED OUT ON EAT SLEEP CONSOLE.
SIMILAR TO BOTH OORCA AND THE
BRAIN STUDY.
THE RESULTS FOR THAT, WE TRACK
OUR METRICS ON A MONTHLY BASIS.
WE'VE HAD OVER 9,000 ENGAGEMENTS
WITH THE EAT SLEEP CONSOLE
CONTENT THAT WE MADE FOR
STAKEHOLDERS.
WE'VE HAD OVER 5,000 ENGAGEMENTS
WITH THE BRAIN INITIATIVE STUDY,
AND WE'VE HAD OVER 19,000
ENGAGEMENTS WITH THE OORCA
FRAMEWORK.
THAT'S JUST SINCE DECEMBER.
SO THAT SHOWS THAT WE'RE
BUILDING AND GROWING THIS
MECHANISM FOR YOU ALL THAT CAN
PUSH YOUR WORK, YOUR HARD WORK
OUT AND FIND MORE STAKEHOLDERS
AND PATIENT GROUPS AND COMMUNITY
ORGANIZATIONS THAT NEED TO HAVE
ACCESS TO THAT INFORMATION.
SO INSTEAD OF TELLING YOU MORE
ABOUT HOW WE PULLED OFF THE
NEARLY 40,000 ENGAGEMENTS, YOU
TALK A LOT ABOUT THE IMPACT
SCORES FOR THE JOURNALS, BUT IF
YOU THINK ABOUT WHAT IS THE
COMMUNITY OR STAKEHOLDER IMPACT
SCORE?
HOW FAR DID YOU PENETRATE THE
STAKEHOLDER AND LIVED EXPERIENCE
FIELDS AND AUDIENCES WITH YOUR
STUDY?
AND THAT'S WHERE WE CAN COME IN
AND HELP YOU SORT OF BRIDGE THAT
GAP.
SO I'M REALLY EXCITED TO
INTRODUCE FIVE OF OUR NATIONAL
ASSOCIATIONS THAT I DESCRIBE AS
THAT DISSEMINATION MACHINE.
WE HAVE DENISE BERTIN-EPP, WHO'S
PRESIDENT AND CEO OF THE
NATIONAL ASSOCIATION FOR
CHILDREN OF ADDICTION.
WE HAVE KATE NICHOLSON, FOUNDER
AND EXECUTIVE DIRECTOR OF THE
NATIONAL PAIN ADVOCACY CENTER.
WE HAVE MICHAEL LITTERER, VICE
PRESIDENT OF THE RWJ BARN BASS
HEALTH INSTITUTE FOR PREVENTION
AND RECOVERY.
WE HAVE SARAH WURZBURG, DEPUTY
DIVISION DIRECTOR FOR BEHAVIORAL
HEALTH AT THE CSG JUSTICE
CENTER, COUNCIL OF STATE
GOVERNMENTS, AND LAST BUT
CERTAINLY NOT LEAST, MY FRIEND
PATTI MCCARTHY, CEO OF FACES AND
VOICES OF RECOVERY.
SO I'M GOING TO HAND IT OVER TO
THEM TO SHARE A LITTLE BIT ABOUT
HOW WE'RE DOING THIS WORK AND
HOW MEANINGFUL THESE PROJECTS
ARE FOR OUR STAKE HOLD ARES.
SO DENISE?
>> GOOD AFTERNOON.
I AM THE CEO AT THE NATIONAL
CENTER FOR CHILDREN IMPACTED BY
ADDICTION.
WE ARE A VERY PROUD HEAL
CONNECTIONS ASSOCIATE PARTNER.
AND AS SOMEONE WHO HAS WORKED IN
THIS FIELD FOR OVER 40 YEARS, I
HAVE NEVER BEEN SO JAZZED UP AND
EXCITED ABOUT IMPLEMENTING WHAT
YOU ALL PRODUCE AT HEAL.
AND IT'S BEEN WONDERFUL TO BE
PART OF THIS GROUP.
IT IS SO INNOVATIVE THAT WE CAN
ACTUALLY GO FROM HAVING A
PAUCITY OF RESEARCH AT THE
TREATMENT AND IMPLEMENTATION
SIDE TO HAVING RESEARCH AT OUR
FINGERTIPS FOR US TO ACTUALLY
USE AND IMPLEMENT.
I'D ALSO LIKE TO THANK JESSICA
HULSEY FOR HER VISION AND
LEADERSHIP AND TO ALL OF YOU
TODAY FOR BEING HERE TO LISTEN
TO US.
NACOA'S MISSION HAS BEEN TO
ELIMINATE THE ADVERSE EFFECTS OF
DRUGS AND ALCOHOL ON CHILDREN
AND FAMILIES.
WE PROVIDE TOOLS TO EDUCATE THE
COMMUNITY ABOUT THE IMPACT OF
SUBSTANCE USE DISORDER ON
CHILDREN AND FAMILIES.
FOR THE LAST 41 YEARS, NACOA HAS
FOSTERED THIS MISSION IN THE
USA, CANADA, EUROPE, AND SOUTH
AMERICA.
THIS MISSION HAS BEEN AND WILL
BE AN UPHILL BATTLE BECAUSE
HISTORICALLY, WE FORGET TO
INCLUDE CHILDREN AND FAMILIES.
THEY'RE ALWAYS AN AFTERTHOUGHT
WHEN WE THINK ABOUT THE DISEASE
OF ADDICTION AND SUBSTANCE USE
DISORDER.
NACOA PROVIDES A BREATH OF FRESH
AIR FOR KIDS WHO ARE CALLING OUT
FOR HELP AND WE BRING THEM TO
THE TABLE TO HEAL.
THESE ARE SOME OF THE
EDUCATIONAL MATERIALS THAT NACOA
PUT OUT IN THE FIELD.
IT INCLUDINGS A MONTHLY
NEWSLETTER, ENGAGING CHILDREN
WHO HAVE EXPERIENCED THE TRAUMA
OF ADDICTION.
OUR REACH OF NACOA IS TO THE
CHILD WELFARE CONSTITUENTS,
FOSTER CARE, TREATMENT COURT,
CHILD PROTECTIVE SERVICES, AND
OTHER PROFESSIONALS WHO WANT TO
HELP KIDS AND FAMILIES RECOVER
AND HAVE HEALTHY FUTURES AFTER
BEING ADVERSELY IMPACTED BY
SUBSTARNES USE DISORDERS.
YOU CAN SEE UP HERE THE SEVEN
Cs, YELLOW POSTER WITH KIDS ON
IT.
THIS IS AN IMPORTANT PIECE
BECAUSE IT SHOWS KIDS THEY DID
NOT CAUSE THIS DISEASE, BUT THEY
CAN HEAL REGARDLESS OF WHETHER
THEIR PARENTS GET INTO RECOVERY.
SOME OF THE PROGRAMS WE OFFER TO
HELP CHILDREN AND FAMILIES HEAL
INCLUDE OUR CHILDREN'S PROGRAM
KIT, WHICH IS AN EDUCATIONAL
SUPPORT FOR KIDS AGED 5 TO 18,
AND YES, WE INCLUDE THE TEENS IN
THIS.
WE HAVE AN EVIDENCE-BASED WHOLE
FAMILY CELEBRATING FAMILIES
CURRICULUM.
THIS IS ON THE NATIONAL
REGISTRY.
IT'S A PROGRAM THAT IS
TRAUMA-INFORMED AND HAS
ADAPTATIONS FOR LATINOS AND
INDIGENOUS COMMUNITIES.
BOTH OF THESE COURSES AND
CURRICULUM ARE OFFERED ON DEMAND
AS WELL AS IN PERSON.
WE HAVE ADDITIONAL PARTNERSHIPS
THAT WE CREATE.
YOU CAN SEE THIS LITTLE GREEN
PUPPET UP IN THE CORNER.
NACOA IS OFTEN BEHIND THE SCENES
SUPPORTING AGENCIES, MESSAGING
AND ADVOCACY FOR RECOVERY AND
THE WELFARE OF CHILDREN.
LAST BEFORE I GET INTO THE HEAL
CONNECTIONS, HERE ARE SOME OF
THE BASIC WAYS YOU CAN GET
INVOLVED WITH YOUR WORK AND A
WITH US.
YOU CAN SEE HERE COA AWARENESS
WEEK, WHICH HAPPENS TO BE NEXT
WEEK.
IT ALWAYS FALLS ON THE WEEK OF
VALENTINE'S BECAUSE 41 YEARS
AGO, THAT'S WHEN THE CHILDREN OF
ALCOHOLICS ORGANIZATION WAS
CREATED.
YOU CAN ALSO SEE A POSTER HERE
FOR NATIONAL DEFLECTION WEEK,
WHERE WE WORK WITH POLICE AND
TRY TO HELP THEM AS THEY
INTERFACE WITH CHILDREN.
AND I'D BE HAPPY TO TALK TO YOU
ABOUT ANY OF THESE PROGRAMS AT
THE END OF THIS.
WE ALSO WILL HELP YOU WITH ANY
GRANT FUNDING THAT YOU HAVE THAT
YOU WANT TO PROVIDE CHILDREN OR
FAMILY CARE.
AND NOW TO THE PIECE I LOVE THE
MOST HERE TODAY.
EAT, SLEEP, CONSOLE STUDY.
THIS WAS ONE OF THE FIRST HEAL
PROJECTS TO BE SUPPORTED BY THE
HEAL CONNECTIONS FOR RESULTS
DISSEMINATION, WHICH I AND WE AT
NACOA ARE VERY PROUD TO BE PART.
IF THE RESEARCHERS ARE HERE
TODAY FOR ESC, I WANT YOU TO
KNOW I WANT TO HUG YOU.
THIS WAS SUCH IMPORTANT RESEARCH
AND SO APPLICABLE TO WHAT WE DO,
SO THANK YOU.
THIS STUDY ASSESSED WHETHER THE
EAT, SLEEP, CONSOLE APPROACH
COULD SAFELY AND EFFECTIVELY
IMPROVE THE FUNCTION AND COMFORT
OF NEWBORNS WITH NEONATAL OPIOID
WITHDRAWAL SYNDROME, OR NOWS,
COMPARED TO THE TRADITIONAL
APPROACH OR MODEL OF CARE.
NACOA AND OUR OTHER NATIONAL
ASSOCIATION PARTNERS
CO-DEVELOPED DIFFERENT PRODUCTS
AND MATERIALS AND DISSEMINATED
THE STUDY RESULTS BROADLY.
YOU CAN SEE HERE THERE WERE
EIGHT ASSOCIATIONS WHO ACTIVELY
ENGAGED THEIR NETWORKS FOR
DISSEMINATION.
WHAT RESULTED FROM A LOT OF
BI-DIRECTIONAL COLLABORATION WAS
A GREAT ARRAY OF COMMUNICATION
PRODUCTS WHICH YOU CAN SEE HERE.
AS JESSICA SAID EARLIER, WE
RECEIVED JUST SHY OF 10 THOWL 10
ENGAGEMENTS IN THE PATIENT AND
STAKEHOLDER FIELDS.
THESE INCORPORATE FEEDBACK FROM
ALL EIGHT OF OUR ASSOCIATION
PARTNERS TO SHARE TO OUR WIDER
NETWORKS.
WE SIMPLIFIED THE INFORMATION TO
ACCOMMODATE VERY DISTINCT
AUDIENCES, INTERFACING WITH ALL
OF OUR CONSTITUENTS AND
INCLUDING THE MATERIALS THAT WE
REQUESTED SO THEY WERE TAILORED
FOR US.
IT WAS INCREDIBLY IMPORTANT FOR
NACOA AND OUR CONSTITUENTS IN
CHILD WELFARE, ALL OF THE
ORGANIZATIONS AND AGENCIES WE
SERVE, SO HAVE THIS INFORMATION.
THIS ISSUE OF HOW CAN I HELP
IMPROVE THE LIFE OF MY CHILD
BORN WITH OPIATES WAS THE
FIRST -- THE ABSOLUTE NUMBER ONE
CALL THAT WE RECEIVED AT NACOA
FOR THE FIRST QUARTER OF 2023.
SO YOU CAN IMAGINE FOR THE FIRST
TIME, WE HAD A SOLUTION THAT WE
COULD OFFER IN COLLABORATION
WITH CARE TEAMS TO HELP THESE
MOTHERS TO SUCCESSFULLY BOND, TO
DISCHARGE EARLIER FROM THE
HOSPITAL, AND TO REDUCE THE
OVERALL COST OF CARE.
THIS PARTNERSHIP WITH THE HEAL
CONNECTIONS AND THOSE OF US AS
ASSOCIATE PARTNERS IS TRULY A
PERFECT MARRIAGE OF RESEARCH AND
APPLICATION.
LIVES AND FAMILIES ARE IMPACTED
IMMEDIATELY WITH THE
INCORPORATION OF THIS RESEARCH
INTO OUR PROGRAMS AND THE ITEMS
I SHOWED YOU WE DELIVER IN THE
COMMUNITY EVERY DAY.
WE CAN DO IT REALTIME.
STAAS FAR AS RELEVANCE FOR NACOA
AND OUR CONSTITUENTS, BEING
INVOLVED IN THE TRANSLATION
PROCESS HAD SO MANY BENEFITS.
AS I MENTIONED EARLIER, WE COULD
HELP MOMS IMMEDIATELY, REALTIME,
SOOTHE THEIR BABIES, HELP THEIR
BABIES.
THE IMMEDIATE APPLICABILITY OF
THIS RESEARCH INTO OUR CONTENT,
FOR INSTANCE, WE WERE GIVEN AN
IMPLEMENTATION TOOLKIT LAST
FRIDAY.
TUESDAY AND WEDNESDAY OF THIS
WEEK, 37 PEOPLE WERE TRAINED IN
THAT IMPLEMENTATION TOOLKIT.
SO IT HAPPENS VERY QUICKLY WHEN
THERE'S THE DESIRE, THE
COLLABORATION AND THE MOTIVATION
IN AN ORGANIZATION LIKE HEAL
CONNECTIONS.
ONE OF THE VERY IMPORTANT
ELEMENTS WAS ALSO THE RURAL
BENEFITS, WHERE WE HAD THE REACH
AND IT AFFORDED THE EQUAL ACCESS
FOR IMPROVED HEALTH STATUS AND
CARE FOR OUR NACOA CLIENTS,
STUDENTS AND PARTNERS ACROSS
THIS COUNTRY AND THROUGHOUT THE
WORLD.
AS I MENTIONED EARLIER, THIS
MARRIAGE BETWEEN RESEARCH AND
CLINICAL APPLICATION IS
ESSENTIAL.
WE NEED TO BE ABLE TO WORK
TOGETHER.
THIS IS A POSITIVE
SOLUTION-ORIENTED FIX.
ALL OF US WORKING AS PARTNERS
AND IN TEAMS IS KEY.
WE HAVE A SERIOUS OPIOID CRISIS
IN THIS COUNTRY THAT ALL OF US
IN THIS ROOM KNOW ABOUT, AND
TOGETHER, WE CAN ACTUALLY HELP
TO REPAIR THIS IN MANY WAYS.
ALL OF YOU IN HEAL HAVE DONE SO
MUCH AROUND STIGMA, INCLUDING
DIVERSE FAMILIES AND CULTURE,
AND CULTURES IN YOUR HEALING
PROCESS, AND TO EMPOWER
PROFESSIONALS TO SERVE AND HELP
OTHERS.
I FEEL VERY HOPEFUL THAT THIS IS
JUST THE BEGINNING OF NEW
FUNDING, OF NEW STRATEGIES, AND
NEW RESEARCH TO CONTINUE TO HELP
CHILDREN AND FAMILIES SO WE CAN
CONTINUE TO BREAK THE IPT
INTERGENERATIONAL CYCLE OF
ADDICTION WITH THEM THROUGH HEAL
AND ALL OF THE WORK YOU DO
TODAY.
THANK YOU SO MUCH FOR YOUR TIME
AND YOUR INTEREST IN HEAL
CONNECTIONS.
>> GOOD AFTERNOON.
MY NAME IS KATE NICHOLSON, I AM
THE EXECUTIVE DIRECTOR AND
FOUNDER OF THE NATIONAL PAIN
ADVOCACY CENTER, A NON-PROFIT
ORGANIZATION THAT TAKES NO
INDUSTRY FUNDING, AND ADVOCATES
TO ADVANCE THE HEALTH AND HUMAN
RIGHTS OF PEOPLE LIVING WITH
PAIN.
WE ARE A COALITION OF
SCIENTISTS, CLINICIANS, PUBLIC
HEALTH AND CIVIL RIGHTS EXPERTS,
AND A DIVERSE GROUP OF PEOPLE
WITH LIVED EXPERIENCE LED BY
PEOPLE LIVING WITH PAIN.
AND WE FOCUS ON ENSURING
EQUITABLE AND EFFECTIVE CARE
THROUGH CHANGING THE NARRATIVE
ABOUT PAIN AND POLICY-BASED
ADVOCACY CHANGE.
MOST IMPORTANTLY, WE ARE A HEAL
CONNECTIONS NATIONAL ASSOCIATION
PARTNER.
SO I WANT TO BEGIN WITH A PHRASE
I'VE SEEN ON OTHER SLIDES TODAY.
THIS IS A FAVORITE OF MINE,
PARTLY BECAUSE MY BACKGROUND IS
AS A DISAB DISABILITY RIGHTS ANL
RIGHTS ATTORNEY AND PARTLY
BECAUSE PAIN IS TH THE CHIEF CAE
OF LONG TERM DISABILITY BOTH
GLOBALLY AND IN THE U.S.
IT BASICALLY STANDS FOR THE IDEA
THAT RESEARCH AND POLICY
SHOULDN'T BE UNDERTAKEN WITHOUT
THE INPUT OF THOSE GROUPS THAT
ARE LIKELY TO BE MOST AFFECTED
BY THEIR OUTCOMES.
THIS IS A POLITICAL AND ETHICAL
MANDATE, BUT IT'S ALSO A
PRACTICAL ONE.
IF YOU WANT YOUR RESEARCH TO
HAVE MEANING.
AND IMPACT.
NICELY, BOTH HEAL AND HEAL
CONNECTIONS HAVE EMBRACED THIS
IDEA BY INCLUDING PEOPLE WITH
LIVED EXPERIENCE AT EVERY STAGE
OF THE RESEARCH PROCESS FROM
INCEPTION THROUGH TRANSLATION.
AND THE TRANSLATIONAL PART IS
REALLY IMPORTANT.
AFTER YOU ASK FOR OUR INPUT IN
WHAT'S IMPORTANT TO STUDY, IT'S
IMPORTANT TO CONVEY THE FINDINGS
OF THOSE STUDIES BACK TO THE
COMMUNITY AND MOST PEOPLE LIVING
WITH PAIN DON'T HAVE ACCESS OR
PAID SUBSCRIPTIONS TO JOURNALS
AND AREN'T REALLY USED TO
READING SCIENTIFIC ARTICLES.
BUT AS IMPORTANTLY, TRANSLATION
TO A BROADER AUDIENCE HELPS US
BE A DISSEMINATION ARMY FOR YOUR
WORK.
ONCE WE HAVE THOSE MATERIALS, WE
CAN TALK ABOUT THE EXCITING NEW
RESEARCH WITH OUR -- IN OUR
MEETINGS WITH POLICY MAKERS AND
THE MEDIA, AND REALLY GET THE
WORD OUT QUICKLY ABOUT WHAT'S
HAPPENING.
SO THE HEAL CONNECTIONS TEAM
REALLY ACTS AS A BRIDGE.
THEY MEET WITH NIH LEADERSHIP
AND STUDY LEADS TO FIGURE OUT
WHAT DISSEMINATION NEEDS THEY
HAVE, BUT THEN THEY ALSO MEET
WITH STAKEHOLDERS AND GROUPS
LIKE OURS.
TO DECIDE WHAT'S GOING
TO BE MOST RELEVANT TO OUR
COMMUNITIES.
AND THIS STUDY WAS REALLY
IMPORTANT FOR PEOPLE LIVING WITH
PAIN FOR A COUPLE OF PRIMARY
REASONS.
ONE OF THE BIGGEST BARRIERS I
HEAR TO PEOPLE LIVING WITH PAIN
IF TREATIN TREATMENT IS THAT THR
SUBJECTIVE REPORTING OF THEIR
CONDITION IS DISMISSED OR
DISBELIEVED, AND OF COURSE THIS
HAPPENS FAR MORE FREQUENTLY IF
SOMEONE HAPPENS TO BE A PERSON
OF COLOR, A WOMAN, LGBTQIA,
SOMEONE WITH DIVERSE
DISABILITIES, OR PEOPLE WHO
EXIST AS MANY DO AT THE
INTERSECTION OF ALL OF THOSE
IDENTITIES.
THERE ALSO STILL SOCIALLY ISN'T
WIDE UNDERSTANDING ABOUT THE
DIFFERENCE BETWEEN ACUTE AND
CHRONIC PAIN, OR THIS IDEA THAT
CHRONIC PAIN CAN BE A DISEASE IN
ITS OWN RIGHT.
AND THE WONDERFUL THING ABOUT
THIS STUDY IS THROUGH IMPLANTED
DEVICES AND IMAGING OF THE
BRAIN, AND ARTIFICIAL
INTELLIGENCE, AND TAKING
PEOPLE'S SUBTIVE REPORTS IS THAT
IT SORT OF ADDRESSES BOTH OF
THOSE THINGS.
IT SHOWED THAT PEOPLE
SELF-REPORTING LINED UP PRETTY
DARN WELL WITH THOSE MORE
QUOTE-UNQUOTE OBJECTIVE
MEASURES.
IT ALSO SHOWED THAT DIFFERENT
AREAS OF THE BRAIN LIT UP WHEN
WE WERE TALKING ABOUT ACUTE AS
OPPOSED TO CHRONIC PAIN.
OBVIOUSLY THERE'S MORE TO DO,
BUT FOR OUR COMMUNITY, IT WAS A
REALLY EXCITING AND IMPACTFUL
STUDY.
SO WE WORKED WITH THE HEAL
CONNECTIONS TEAM AND JESS TO
COME UP WITH A SERIES OF
PRODUCTS.
WE CAME UP WITH SEVEN PRODUCTS,
A WEBPAGE A ONE-PAGER, A
TOOLKIT, SOCIAL MEDIA BLASTS,
E-BLASTS, A LAY PERSON SUMMARY
AND A SERIES OF GRAPHICS.
AND THEN WE DISSEMINATED THROUGH
THREE PARTNER ORGANIZATIONS,
NPAC, THE ORGANIZATION I'M
AFFILIATED WITH, THE CHRONIC
PAIN RESEARCH ALLIANCE, WHICH IS
DIRECTED BY KRISTEN VEESLEY WHO
MANY OF YOU MAY HAVE WORKED WITH
AND OF COURSE THE U.S.
ASSOCIATION FOR THE STUDY OF
PAIN, SHOUT OUT TO ONE OF OUR
NEW PARTNERS WHO'S THE
PRESIDENT-ELECT.
ANYWAY, BY USING THESE NETWORKS,
WE WERE ABLE TO GET OVER 5,000
ENGAGEMENTS.
SO BIG PICTURE AS JUST
MENTIONED, REALLY THE IDEA
BEHIND HEAL CONNECTIONS IS
MEANINGFUL BI-DIRECTIONAL
COMMUNICATION, AND THE TEAM DOES
THIS IN A FEW BASIC WAYS.
THE FIRST IS THROUGH HOSTING
QUARTERLY LISTENING SESSIONS.
THAT INVOLVE BOTH NIH
LEADERSHIP, AND THE STAKEHOLDER
AND PATIENT ENGAGEMENT GROUPS.
THE SECOND IS THROUGH
CO-PRODUCTION OF MATERIALS.
AND LET ME BE THE FIRST TO TELL
YOU THAT IT IS ABSOLUTELY TRUE
THAT STAKEHOLDER EDITS ARE
INCORPORATED AND THAT THE
MATERIALS ARE NOT DISTRIBUTED
UNTIL EVERYONE'S CONCERNS HAVE
BEEN MET.
WHICH IS SOMETHING WE REALLY
APPRECIATE ABOUT THIS EFFORT.
AND THERE'S ACTUALLY PRETTY GOOD
DATA THAT ENGAGING END USERS IN
STUDY TRANSLATION AND KNOWLEDGE
TRANSLATION CREATES, YOU KNOW,
GREAT RESULTS, INCLUDING LEADING
TO THE ADOPTION OF
EVIDENCE-BASED PRACTICES FOR
EXAMPLE, OR CREATING A SENSE OF
OWNERSHIP THAT SPURS ACTION.
THE FINAL PILLAR THAT WAS REALLY
IMPORTANT FOR THE FIRST YEAR,
YEAR AND A HALF, OF HEAL
CONNECTIONS WAS THE LANDSCAPE
ANALYSIS, WHICH WAS A
PARTNERSHIP BETWEEN NIH AND THE
STAKEHOLDERS TO IDENTIFY THE
BARRIERS AND THE CHALLENGES AND
THE UNIQUE COMMUNICATION NEEDS
OF ALL OF THESE DIFFERENT GROUPS
THAT ALIGNED WITH HEAL
PRIORITIES.
I WAS VERY HONORED TO BE
INVOLVED IN THIS LANDSCAPE
ANALYSIS.
THE LANDSCAPE ANALYSIS ABOUT
PAIN, WHICH WE CO-PRODUCED,
ALONG WITH JESS' TEAM WHICH OF
COURSE THEY DID THE HEAVY
LIFTING ON, IDENTIFIED A NUMBER
OF BARRIERS AND CHALLENGES.
ONE WAS THE LACK OF EDUCATION
AND TRAINING IN CLINICIANS ABOUT
PAIN, PARTICULARLY AMONG PRIMARY
CARE PROVIDERS, AND ALSO ISSUES
WITH THE WORKFORCE IN TERMS OF
THERE NOT BEING ENOUGH PAIN
MANAGEMENT PROVIDERS OR EXPERTS
OUT THERE.
BARRIERS TO QUALITY TREATMENT
AND SERVICES IS PROBABLY THE
NUMBER ONE THAT WE HEAR AGAIN
AND AGAIN AND AGAIN.
IDENTIFIED AREAS WHERE THERE
WERE GAPS IN SYSTEMS
COLLABORATING, PROBLEMS WITH
LINKAGE SO THAT PEOPLE WITH PAIN
WESPENT A LOT OF THEIR TIME TRYG
TO CONNECT THE DOTS, WHICH SOME
CONSIDER TO BE A FULL-TIME JOB.
ANOTHER BARRIER WAS THE LACK OF
FUNDING RELATIVE TO PAIN'S SORT
OF PREVALENCE AND DISABLING
CONSEQUENCES AND COSTS.
A BIG ONE WAS ONE SIZE FITS ALL
APPROACHES, WHICH REALLY MAKES
VERY LITTLE SENSE WHEN WE'RE
TALKING ABOUT A HUGE UMBRELLA
CATEGORY LIKE CHRONIC PAIN THAT
CAN INVOLVE A LOT OF DIFFERENT
DISEASES, AND A LOT OF DIFFERENT
NEEDS, AND IN WHICH WE KNOW THAT
INDIVIDUALIZED WHOLE PERSON
BIOPSYCHOSOCIAL CARE IS BEST,
AND FINALLY, WAS THE LACK OF
DATA AND RESEARCH IN GENERAL, SO
IT'S IMPORTANT, AGAIN, TO
TRANSLATE WHAT IS HAPPENING TO
THE COMMUNITY.
THARNTIONTHANKS SO MUCH, AND I N
IT OVER TO SARAH.
>> OKAY.
AND WE'RE BACK.
THANK YOU.
SO I'M SARAH.
I'M GOING TO FIRST TELL YOU A
LITTLE BIT ABOUT THE
ORGANIZATION I WORK FOR, AND
THEN WE'LL GET INTO HOW WE'VE
BEEN HELPING ON THIS REALLY
IMPORTANT WORK TO THINK ABOUT
HOW TO GET RESEARCH INTO POLICY,
PLANNING, PRACTICE AND
IMPLEMENTATION.
SO THE ORGANIZATION I WORK FOR
IS CALLED THE COUNCIL OF STATE
GOVERNMENTS.
WE'RE A NON-PARTISAN, NON-PROFIT
ORGANIZATION, IT'S ACTUALLY A
MEMBERSHIP ORGANIZATION OF ALL
THREE BRANCHES OF GOVERNMENT SO
BOTH APPOINTED AND ELECTED
OFFICIALS ACROSS THE BOARD.
CSG AS YOU CAN SEE ON THE LITTLE
LOGO IS REALLY FOCUSED ON
GETTING STATES TO IMPLEMENT BEST
PRACTICES ACROSS THE COUNTRY.
AND THEN I WORK IN THE CSG
JUSTICE CENTER, WHICH WE FOCUS
ON DEVELOPING RESEARCH-DRIVEN
STRATEGIES TO INCREASE PUBLIC
SAFETY AND STRENGTHEN
COMMUNITIES.
SO WHAT THAT LOOKS LIKE IS WE
FOCUS ON BREAKING THE CYCLE OF
INCARCERATION, ADVANCING HEALTH
EQUITY AND OPPORTUNITY, SO
TRYING TO GET THROUGH SOME OF
THE BARRIERS THAT WE SEE IN THE
COMMUNITY AROUND ACCESS TO
BEHAVIORAL HEALTHCARE, HOUSING,
ECONOMIC MOBILITY, RACIAL AND
GENDER INEQUALITY AS WELL, AND
BRING DIVERSE STAKEHOLDERS
TOGETHER TO TRY TO PLAN EFFORTS
THAT WILL SUPPORT WORK FOR THEM.
AND WE USE DATA TO IMPROVE
SAFETY AND JUSTICE.
SO WE ARE REALLY EXCITED TO TALK
ABOUT THE OPIOID OVERDOSE
REDUCTION CONTINUUM OF CARE OR
OORCCA AND RESULTS TO THE FIELD.
THIS IS SUPER EXCITING BECAUSE
WHAT THIS REALLY DID FOR POLL
SATISFY MAKERS IS REALLY DISTELL
A LOT OF RESEARCH AND PRACTICES
INTO SOMETHING THAT WAS
DIGESTIBLE AND USABLE.
SO REALLY A WATERSHED MOMENT IN
TERMS OF DISTILLING INFORMATION
THAT NEEDED TO GET OUT THERE TO
TRY TO ADDRESS OPIOID OVERDOAS
DEOVERDOSEDEATHS ACROSS THE COU.
THIS OUTLINED 19 ESSENTIAL -- TO
TRY TO DEVELOP MULTI-SYSTEMIC
EFFORTS TO ADDRESS THIS.
AND YOU CAN SEE ON THE RIGHT
SIDE IS THE ENGAGEMENT.
OUR ORGANIZATION IS ONE OF THE
16 PARTICIPATING ASSOCIATIONS IN
THIS.
BUT YOU KNOW, 19,000 ENGAGEMENTS
REPRESENTS MANY, MANY PEOPLE.
I THINK THAT'S REALLY TELLING OF
HOW IMPORTANT AND NEEDED THIS
INFORMATION WAS, SO IT HAS
INFORMATION ON WEBINARS, ON
SOCIAL MEDIA, ON WEBSITES, ON
PARTNER ENGAGEMENT, EMAIL
DISSEMINATION.
SO THERE'S A LOT OF DIFFERENT
WAYS IN WHICH THE INFORMATION ON
THE STRATEGY IS GETTING OUT
THERE SO IT CAN INFORM
POLICYMAKING, WHICH COULD BE
LEGISLATION, IT COULD BE
ADMINISTRATIVE POLICY, AS WELL
AS ACTUALLY MOVING TOWARDS
IMPLEMENTING THESE STRATEGIES IN
COMMUNITIES.
SO THIS IS THE PART TO ME THAT'S
MOST EXISTING ABOUT THIS, IS
THAT THERE'S ALL THESE DIFFERENT
PRODUCTS THAT TALK ABOUT THIS IN
DIFFERENT WAYS FOR DIFFERENT
AUDIENCES.
AND I THINK FROM THE EXPERIENCE
AND THE WORK THAT I DO, THIS IS
REALLY IMPORTANT.
SO YOU HAVE THINGS LIKE THE
PRACTICE GUIDE FROM SAMHSA, AND
ONE OF THE THINGS THAT I OVERSEE
IS SOME TRAINING AND TECHNICAL
ASSISTANCE TO THE DEPARTMENT OF
JUSTICE, AND WE WORK ON TWO
MAJOR FEDERAL GRANT PROGRAMS,
THE JUSTICE AND MENTAL HEALTH
COLLABORATION PROGRAM, AND THE
SECOND CHANCE ACT HEALTH AND
HOUSING.
SO IT'S REALLY WORKING ACROSS
THE JUSTICE SYSTEM TO ADDRESS
MENTAL ILLNESS, SUBSTANCE USE
DISORDERS AND CO-OCCURRING
DISORDERS.
AS THE TA PROVIDER, WE CAN
ACTUALLY FOLLOW UP WITH THEM ON
THIS, SO WE TALK TO THEM
MONTHLY, WE HAVE REGULAR
COMMUNICATION.
SO FOR THAT AUDIENCE, THAT WAS
LIKE THE PERFECT THING BECAUSE
WE CAN ACTUALLY TAKE IT AND GO
USE IT WITH PEOPLE, AND HAVE
THEM FACILITATE CONVERSATIONS IN
THEIR COMMUNITY ABOUT WHAT
STRATEGIES THEY MIGHT WANT TO
ADD THAT THEY'RE NOT ALREADY
USING.
THERE'S ALSO THE GUIDE FOR
POLICY MAKERS.
WE ALREADY TOUCHED ON THIS A
LITTLE BIT BUT THE COUNCIL OF
STATE GOVERNMENTS, THAT'S WHAT
WE'RE ABOUT.
WE'RE ABOUT GETTING AT POLICY
MAKERS AND OTHER STATE
GOVERNMENT OFFICIALS.
BUT THEN THERE'S ADDITIONAL
OPTIONS.
SO AN INFOGRAPHIC THAT COULD
CATCH SOMEONE'S ATTENTION AND
THEN HOPEFULLY THEY GO AND
ACTUALLY SEE THE 19 STRATEGIES
BECAUSE OF THEIR INTEREST IN THE
INFOGRAPHIC.
AND FOR US, SOCIAL MEDIA HAS
ACTUALLY BEEN A BIG THING
LATELY, JUST TO INCREASE
ENGAGEMENT IN GETTING MESSAGES
OUT THERE TO A VARIETY OF
GOVERNMENT OFFICIALS LIKE MOST
OF THE GOVERNMENT OFFICIALS THAT
WE WORK WITH ARE ACTUALLY ON
LINKEDIN AND THEY HAVE OTHER
PAGES THAT THEY FOLLOW, SO I
THINK IT'S REALLY EFFECTIVE TO
HAVE THESE DIFFERENT WAYS OF
MARKETING TO THEM, INCLUDING
BLOGS, THERE WAS ALSO A WEBINAR
HELD LAST WEEK.
WE DISSEMINATED THAT THROUGH OUR
LISTSERV, WHICH IS 17,000
PEOPLE, SO RIGHT THERE YOU'RE
GETTING THE WORD OUT TO STATE
LOCAL GOVERNMENT OFFICIALS AS
WELL AS SOME OF THE GRANT SITES
WE'RE WORKING THAT ARE ACTUALLY
IMPLEMENTING THESE PROGRAMS
DIRECTLY WITHIN CRIMINAL LEGAL
SETTINGS.
AND IN ATTENDING THAT, ONE OF
THE THINGS THAT I LOVE TO HEAR
ABOUT WAS THE FOUR STATES THAT
WE'RE TALKING ABOUT, THE
COMMUNITY CASE STUDIES THAT THEY
IMPLEMENTED, AND WHAT WE HEAR
FROM A LOT OF PEOPLE WHO ARE
ACTUALLY COULDING THE PLANNING
AND IMPLEMENTATION FOR THESE
EFFORTS IS THEY JUST WANT TO
KNOW WHO DID IT AND DID IT WORK.
SO HEARING FROM THOSE SITES IS
SO IMPORTANT BECAUSE THAT
INSPIRES THEM LIKE, OKAY, EVEN
IF IT TOOK THEM A YEAR, TWO
YEARS, THREE YEARS, OFTEN FIVE
YEARS TO IMPLEMENT A PROGRAM, IF
YOU CAN HEAR AND GET GUIDANCE
FROM OTHER PEOPLE WHO HAVE DONE
IT, IT'S REALLY INSPIRATIONAL
AND I THINK MAKES A REALLY HUGE
DIFFERENCE.
SO I THINK THE KEY PIECE OF THIS
IS JUST LIKE MAKING THINGS
DIGESTIBLE FOR DIFFERENT
AUDIENCES AND FOR POLICY MAKERS,
THEY'RE REALLY BUSY, SO IF WE
CAN GET THINGS THAT'S DIGESTIBLE
TO THEM, THAT'S REALLY CLEAR TO
THEIR STAFF, TO THEIR TEAM
MEMBERS SO THEY CAN DO
LEGISLATION BUT ALSO
ADMINISTRATIVE POLICY CHANGES OR
CHANGES WITHIN THE COURT SYSTEM
ARE JUST AS IMPORTANT AS WELL.
SO IT'S REALLY IMPORTANT.
GIVEN THE SCOPE OF THE OPIOID
CRISIS, AS MANY PEOPLE WE CAN
REACH, THE BETTER WITH THESE
STRATEGIES AND REALLY TRYING TO
IMPACT POLICY MAKERS SO THEY CAN
USE THESE STRATEGIES TO INFORM
WHAT THEY'RE DOING IN WRITING
POLICY, IN DOING LEGISLATION AS
WELL, MAKING IT DIGESTIBLE AND
EASY FOR THEM TO UNDERSTAND, BUT
THEN FOR PEOPLE TO ACTUALLY PLAN
AND IMPLEMENT THINGS THAT FOLLOW
THESE PRACTICES, WHICH IS THE
IMPORTANT END GOAL THAT WE WOULD
LIKE.
SO I THINK WHAT'S BEEN EXCITING
FOR ME IS THAT THIS IS REALLY A
ROAD MAP TO SUPPORT RESEARCH TO
PRACTICE TO THINK ABOUT HOW
STATES AND COMMUNITIES CAN
FOLLOW GUIDELINES THAT IS
INFORMED BY THE RESEARCH THAT
TRULY WORKS TO TRY TO PLAN AND
IMPLEMENT THESE STRATEGIES.
SO IT'S REALLY BEEN EXCITING TO
BE A PART AND HELPING ON THE
DISSEMINATION OF THIS, AND
THANKS FOR THE OPPORTUNITY.
>> GOOD AFTERNOON, EVERYONE.
IS THIS ON?
OKAY.
I'M GOING TO GO A LITTLE OFF
SCRIPT BUT I THINK IT WILL BE
RELEVANT FOR THE CONVERSATION
TODAY.
SO I'M MIKE LITTERER FROM RWJ
BARNABAS HEALTH.
WE ARE NEW JERSEY'S MOST
COMPREHENSIVE ACADEMIC
HEALTHCARE SYSTEM.
WE SERVE ABOUT A THIRD OF NEW
JERSEY'S COUNTIES, BUT THAT
REPRESENTS OVER 50% OF THE
POPULATION.
WE HAVE ACUTE CARE HOSPITALS AND
WE ALSO HAVE A CLOSE PARTNERSHIP
WITH RUTGERS, WHO IS OUR
ACADEMIC PARTNER.
I PERSONALLY WORK ON THE TEAM AT
THE INSTITUTE FOR PREVENTION
RECOVERY.
WE ARE A SOLELY GRANT FUNDED ARM
OF THE HEALTHCARE SYSTEM. WE
PROVIDE PREVENTION SERVICES,
RECOVERY SUPPORT SERVICES,
TOBACCO CESSATION SERVICES, AND
A FEW OTHER THINGS.
AND I DON'T SAY THOSE THINGS TO
SAY WHO I AM, BUT MORE TO BRING
RELEVANCE TO, I THINK, SOME OF
THE CONVERSATION FOR TODAY.
THROUGH OUR PEER RECOVERY
PROGRAM, WE SERVE ABOUT 20,000
PATIENTS A YEAR.
WE ACTUALLY JUST SERVED 100,000
PATIENTS SINCE THE INCEPTION OF
OUR PROGRAM.
WE EMPLOY 120 SL FULL-TIME
RECOVERY SPECIALISTS, ALL
INDIVIDUALS WHO ARE IN RECOVERY
THEMSELVES.
THEY WORK 24 HOURS A DAY, 7 DAYS
A WEEK IN OUR HOSPITALS, IN OUR
COMMUNITIES.
AND JUST ARE ABSOLUTELY THE
LIFEBLOOD OF OUR PROGRAM, FULLY
INTEGRATED INTO THE CARE TEAM.
WE ALSO DO PREVENTION SERVICES
IN SOME OF OUR MOST AT-RISK
COMMUNITIES IN NEW JERSEY.
SO WE DO A LOT OF WORK.
AND I WILL TELL YOU, WHEN I CAME
HERE, I WAS A LITTLE UNSURE, I
WASN'T SURE IF I WAS GOING TO
FIT IN OR UNDERSTAND A LOT OF
THE THINGS THAT WERE GOING TO BE
TALKED ABOUT, I'M NO RESEARCHER,
I DO SEE MYSELF AS A CONSUMER.
BUT I QUICKLY REALIZED THAT IT
WAS AMAZING TO SEE HOW ALIGNED
THE TOPICS OF THIS CONFERENCE
WERE TO THE WORK THAT WE DO
EVERY DAY IN NEW JERSEY.
IT WAS -- THERE IS ALMOST NOT A
SINGLE TOPIC, I ACTUALLY WALKED
AROUND THE POSTER ROOM AND LET'S
SAY THERE WAS 50 POSTERS, I
THINK I TOOK PICTURE OF ABOUT 40
POSTERS.
IT WAS AMAZING TO SEE.
BUT I WILL TELL YOU, I HAD NO
AWARENESS OF ALMOST ANY OF THE
STUDIES THAT WERE HIGHLIGHTED IN
THE POSTER.
ONE OF THE OTHERS THINGS THAT
WE'RE VERY FORTUNATE IS WE
WORKED VERY CLOSELY WITH THE
RUTGERS ADDICTION RESEARCH -- I
SHOULD PROBABLY BE FORWARDING MY
SLIDES, BUT -- WE WORKED VERY
CLOSELY WITH THE RUTGERS
ADDICTION RESEARCH CENTER.
THAT'S BEEN ESTABLISHED I GUESS
ABOUT TWO YEARS OR SO, IT'S LED
BY DR. DANIEL DIK, WHO'S AMAZING
TO WORK WITH, ONE OF OUR CLOSE
PARTNERS, SO WE HAVE FULL ACCESS
TO A VERY LARGE COMPREHENSIVE
RESEARCH CENTER FOCUSED ON
ADDICTION.
BUT ACTUALLY A STORY, NINA AND I
CONNECTED IN THE LOBBY BEFORE,
AND NINA AND I HAVE WORKED
TOGETHER, SHE'S WORKED WITH OUR
TEAM, DID EXTENSIVE EVALUATION
OF OUR PEER RECOVERY PROGRAM.
WE WORKED VERY CLOSELY.
WE ARE ACTUALLY -- WE HELPED
CHANGE LEGISLATION IN NEW JERSEY
TO DISTRIBUTE NALOXONE IN OUR
EMERGENCY ROOM, SO OUR PEER
SPECIALISTS CAN ACTUALLY HAND A
KIT TO THE PATIENT, NOT A
SCRIPT.
AND WE PARTNERED WITH NINA AND
HER TEAM TO DISTRIBUTE THAT
NALOXONE.
SO WE WORK EVERY DAY.
VERY
CLOSELY.
AND I ACTUALLY JUST FOUND OUT
HERE THAT NINA ALSO HAD A STUDY
RECENTLY PUBLISHED, AND I HAD NO
IDEA THAT THAT HAD TAKEN PLACE.
I HIGHLIGHT THIS BECAUSE THERE
IS SUCH TREMENDOUS RESEARCH
HAPPENING, BUT THERE IS SUCH A
TREMENDOUS GAP IN GETTING TO THE
HANDS OF THE FOLKS THAT ARE
IMPLEMENTING.
THE OTHER THING, TOO, IS I AM
VERY FORTUNATE, WE HAVE A DATA
ANALYTICS AND RESEARCH AND
DEVELOPMENT TEAM.
ELLIOTT, BRITTANY, RENA, SUPER
INCREDIBLY SMART TEAM OF MIXED
METHODS RESEARCHERS.
BUT WE ONLY HAD THAT BECAUSE
ABOUT SEVEN YEARS AGO, WE
PRIORITIZED THAT EVERY GRANT WE
WRITE, WE INCLUDE ANALYTICS.
BECAUSE HOW CAN WE BE DOING THIS
WORK IF WE DON'T LOOK AT WHAT'S
WORKING, WHAT'S NOT.
SO ABOUT 10% OF EVERY GRANT THAT
WE WRITE, WE INCLUDE CAPACITY
BUILDING FOR OUR DATA ANALYTICS
TEAM.
I THINK THAT SHOULD BE THE SAME
THING FOR RESEARCH.
IT'S NOT THE GOAL OF PUBLISHING,
IT'S THE GOAL OF GETTING INTO
THE HANDS OF PEOPLE TO TRANSLATE
THAT WORK INTO ACTION.
SO I THINK EVERY RESEARCHER
SHOULD HAVE A PORTION OF THEIR
BUDGET, THEIR TIME, AND HOW ARE
THEY ACTUALLY GOING TO GET INTO
THE HANDS OF SOMEONE LIKE ME WHO
COMES TO A MEETING LIKE THIS SO
INTERESTED IN SO MANY OF THE
TOPICS THAT ARE SO RELEVANT TO
THE WORK THAT WE DO, AND I HAD
NO IDEA.
SO ONE OF THE OTHER THINGS IS I
WANT TO HIGHLIGHT -- YOU KNOW,
WE'RE NOT A NATIONAL
ASSOCIATION.
SO MANY OF MY PARTNERS HERE ON
THE TABLE REPRESENT
ORGANIZATIONS ACROSS THE
COUNTRY.
WE'RE A HEALTHCARE SYSTEM IN NEW
JERSEY.
BUT WHAT I DID REALIZE WAS, IS
THAT WE HAVE OUR TACKLING
ADDICTION TASK FORCE CHAIRED BY
DR. CHRISTOPHER FREER, HEAD OF
OUR EMERGENCY HOSPITAL SERVICE
LINE AS WELL AS MY BOSS, CONNIE
GREEN, OUR SENIOR VICE
PRESIDENT.
IT'S A MULTIDISCIPLINARY TEAM
THAT HAS NURSING, PHYSICIANS,
I.T., EVERY DISCIPLINE WITHOUT
THE -- THROUGHOUT THE HEALTHCARE
SYSTEM, AND THAT'S WHERE WE MAKE
OUR DECISIONS BUT THAT'S ALSO
WHERE WE EDUCATE THEM.
SO A GREAT EXAMPLE O IS THE EAT,
SLEEP, CONSOLE TOOLKIT LAST
WEEK.
WE DELIVER OVER 20,000 BABIES A
YEAR IN NEW JERSEY.
WE'RE THE LARGEST DELIVERER OF
BABIES OF NINE BIRTHING
HOSPITALS.
WE WORK VERY CLOSELY WITH OUR
SEEN YOUR VICE PRESIDENT OF
WOMEN'S SERVICES.
IN ONE EMAIL, I'M ABLE TO EMAIL
THAT TOOLKIT TO SUZANNE, SHE
THEN SENDS TO ALL HER OB CHAIRS
ACROSS OUR ENTIRE SYSTEM, AND
WITHIN A FEW DAYS, POTENTIALLY
27,000 BABIES ARE IMPACTED BY
THAT RESEARCH.
BUT IF IT WAS A RESEARCH STUDY
AND A 20-PAGE RESEARCH ARTICLE,
I WOULD PROBABLY EMAIL THAT AND
NO ONE WOULD READ IT.
I FORTUNATELY HAVE FOLKS LIKE
DANIELLE AND NINA AT THE RUTGERS
ADDICTION RESEARCH CENTER,
ELLIOTT, RENA AND BRITTANY WHO
TRANSLATE IT FOR ME AND DUMB IT
DOWN, BUT THERE'S ONLY SO MUCH
IN THAT CAPACITY.
SO I WAS REALLY EXCITED WHEN I
FOUND OUT WHAT ADDICTION -- WHAT
THE HEAL CONNECTIONS PROGRAM
WAS.
AND I REALLY ENCOURAGE YOU ALL
AS RESEARCHERS TO GET THESE
THINGS IN OUR HANDS BECAUSE WE
CAN ACT ON IT VERY QUICKLY WHEN
IT'S DIGESTIBLE.
MY LAST PIECE BEFORE I HAND IT
OVER IS, FOR ME, THE RESEARCH
AND THE INFORMATION CAUSES A
FORK IN THE ROAD.
THAT FORK IN THE ROAD DOES TWO
THINGS.
IT HELPS ME WORK ON CREATING
POLICY, MAKING SURE THAT THE
POLICIES OF OUR CARE DELIVERY,
OUR DOCUMENTATION FOLLOW BEST
PRACTICES, AS WELL AS CHANGING
THE PRACTICE.
SO WE GET INTO THE HANDS OF THE
DOCTORS AND THE NURSES, WE GET
INTO THE HANDS OF THE
ADMINISTRATORS, AND THAT ROAD
SPLIT AND WE CAN WORK IN
PARALLEL ON GETTING THIS DONE.
THAT ROAD EVENTUALLY MERGES BACK
WHERE PRACTICE MEETS POLICY, AND
THAT'S WHERE THE REAL CHANGE
MAKES.
I NEED THE INFORMATION FROM THIS
RESEARCH IN MULTIPLE TOOLS, SO I
CAN EDUCATE A DOCTOR, AN
ADMINISTRATOR, A NURSE, THE
COMMUNITY, OUR PEER SPECIALISTS.
SO I THINK I'M -- I FEEL VERY
FORTUNATE TO BE A PART OF THIS
HEAL CONNECTIONS TO NOT ONLY
HAVE THAT INPUT, BUT TO HAVE THE
TOOLS, THAT BI-DIRECTIONAL TOOL
FOR US, AND ALSO TO HOPEFULLY
INFORM FUTURE RESEARCH.
SO I WILL LEAVE IT AT THAT, BUT
I ENCOURAGE YOU ALL TO PLEASE
PARTICIPATE, AND DUMB IT DOWN,
GET TO SOMEONE LIKE ME THAT CAN
DO SOMETHING WITH IT.
I STILL GOOGLE WHAT A PEE TEST
IS, SO THAT'S WHERE I'M AT.
BUT IF YOU CAN GET IT DOWN TO
THAT LEVEL, WE CAN ACT ON IT
MUCH QUICKER.
SO THANK YOU.
>> HI, GOOD AFTERNOON.
MY NAME IS PATTY MCCARTHY, AND I
AM A WOMAN IN LONG TERM RECOVERY
FROM ALCOHOL AND DRUG ADDICTION.
AND -- WHERE AM I HERE?
THERE WE ARE.
SO IF IT WASN'T FOR MY RECOVERY,
I WOULDN'T BE A MOTHER,
GRANDMOTHER, TAXPAYER,
HOMEOWNER, VOTER.
AND I CERTAINLY WOULDN'T BE HERE
TODAY AS THE CEO OF FACES &
VOICES OF RECOVERY.
WE ARE A NATIONAL ADVOCACY AND
EDUCATION ORGANIZATION BASED IN
WASHINGTON, D.C., AND WE BEGAN
OVER 20 YEARS AGO TO PUT A FACE
AND A VOICE ON RECOVERY.
AND OUR MISSION REALLY IS TO
CHANGE THE WAY THE PUBLIC SEES
ADDICTION AND RECOVERY.
SO I'LL TELL YOU A LITTLE BIT
MORE ABOUT WHAT WE DO, BUT
REALLY ULTIMATELY, IT'S TO MAKE
RECOVERY POSSIBLE FOR EVEN MORE
AMERICANS AND CHANGE THAT
TRAJECTORY FOR GENERATIONS TO
COME AND HELP FUTURE GENERATIONS
AND THE CHILDREN THAT ARE OFTEN
THE BIGGEST WINNERS IN THE
RECOVERY PROCESS.
SO AS A NATIONAL ORGANIZATION,
WE HAVE QUITE A REACH.
WE ACTUALLY HAVE A NETWORK, IT'S
AN ASSOCIATION.
WE HAVE OVER 200 ALLIANCE
MEMBERS SO THERE ARE THE MEMBERS
OF THE ALLIANCE FOR RECOVERY
CENTERED ORGANIZATIONS.
AND MANY OF THOSE ARE RECOVERY
COMMUNITY ORGANIZATIONS, WHICH
ARE GRASSROOTS ORGANIZATIONS LED
AND RUN BY THE RECOVERY
COMMUNITY IN STATES ACROSS THE
COUNTRY.
WE ARE ALSO A GLOBAL -- THE
LARGEST GLOBAL RECOVERY ADVOCACY
NETWORK IN THE WORLD.
WE HAVE BEEN WORKING HARD BY
TALKING WITH MEMBERS OF
CONGRESS, TALKING WITH THE WHITE
HOUSE, OTHER FEDERAL AGENCIES,
TO MAKE SURE THAT THERE IS
FUNDING OUT THERE FOR RECOVERY
SUPPORT SERVICES AND RECOVERY
PROGRAMS AND RECOVERY
ORGANIZATIONS.
SO OUR ACTUAL REACH IS, YOU
KNOW, ABOUT 80,000 MEMBERS ON A
REGULAR BASIS RECEIVING OUR
INFORMATION.
SOME OF THE PROGRAMS WE'VE
STARTED AND DEVELOPED OVER THE
PAST 20 YEARS IS AS I MENTIONED
THE ALLIANCE.
WE SUPPORT AND UNITE THOSE
200-PLUS ORGANIZATIONS AROUND
THE COUNTRY BY SHARING KNOWLEDGE
AND RESOURCES WITH THEM.
AND NETWORKING AND BRINGING THEM
TOGETHER FOR AN ANNUAL
CONFERENCE, WE BRING THEM TO
CAPITOL HILL.
AS YOU SAW ON THE LAST SLIDE, TO
TALK WITH THEIR MEMBERS OF
CONGRESS.
AND THEN WE ALSO HAVE CAPRSS,
THE ONLY ACCREDITING BODY IN THE
U.S. SOLELY FOR ORGANIZATIONS
THAT PROVIDE PEER RECOVERY
SUPPORT SERVICES.
WE OPERATE THE NATIONAL RECOVERY
INSTITUTE, WHICH IS A NATIONAL
PEER-RUN TRAINING AND TECHNICAL
ASSISTANCE CENTER.
SO WE'RE TRAINING ORGANIZATIONS
TO INTEGRATE AND IMPLEMENT
EFFECTIVE PEER SERVICES ACROSS
THE COUNTRY.
WE'RE ALSO TRAINING THE PEER
WORKFORCE WITH CONTINUING
EDUCATION UNITS.
WE WORK CLOSELY WITH ANY
ORGANIZATION THAT WANTS -- OR
STATE ENTITY THAT WANTS TO BUILD
A RECOVERY INFRASTRUCTURE TO
MAKE RECOVERY-READY COMMUNITIES
ACROSS THE NATION.
OUR RECOVERY DATA PLATFORM IS A
CLOUD-BASED DATA PLATFORM THAT
COLLECTS INFORMATION FROM PEER
SERVICES ACROSS THE NATION.
WE HAVE OVER 120 ACTUAL
PARTICIPANTS NOW THAT HAVE
ENGAGED, THOSE ARE THE PEOPLE
RECEIVING SERVICES, AND SO THERE
ARE STATE ENTITIES AND COMMUNITY
ORGANIZATIONS THAT USE THE
PLATFORM, AND WE ARE VERY
EXCITED TO TRY TO -- WHEN WE
FINALLY FIND A WAY TO SHARE THAT
INFORMATION, THAT DATA THAT HAS
NOT BEEN EVALUATED OR RESEARCHED
AT THIS POINT.
SO IT'S LIKE A GOLD MINE OF
DATA.
THIS IS JUST A MAP OF ALL OF OUR
ORGANIZATIONS AROUND THE
COUNTRY.
IT DOESN'T REALLY SHOW THAT WE
ALSO HAVE ORGANIZATIONS
INTERNATIONALLY.
AND IN TERRITORIES ACROSS THE
COUNTRY.
AS KATE MENTIONED EARLIER, NOT
ABOUT US WITHOUT US, FOR THE
PAIN COMMUNITY, THIS IS REALLY
WHAT FACES & VOICES OF RECOVERY
DOES IN POLICY-MAKING DECISIONS
SUCH AS, YOU KNOW, OPIOID
ABATEMENT COUNCILS, OPIOID
SETTLEMENT.
ALSO AT THE STATE LEVEL ON
BEHAVIORAL HEALTH, BLACK --
COUNCILS, THINGS LIKE THAT, WE
HELP GROUPS AND INDIVIDUALS TO
LEARN HOW TO ADVOCATE AND BE A
VOICE ON THOSE COUNCILS AND
THOSE COMMITTEES.
WE ALSO TRAIN PEOPLE LIKE A
SPEAKERS BUREAU AROUND HOW TO BE
EFFECTIVE IN POLICYMAKING, AND
PEOPLE IN RECOVERY.
SO REALLY THE IMPORTANT PIECE
HERE AND WHY WE'RE HERE WITH THE
HEAL CONNECTIONS AND WORKING
CLOSELY WITH THESE ORGANIZATIONS
AND JESS AT THE ADDICTION POLICY
FORUM IS BECAUSE THIS BRINGS ALL
OF US TOGETHER AS AN INCREDIBLE
FORCE TO DISSEMINATE THE
INFORMATION BUT ALSO ADVISE.
WE'RE NOT JUST BEING TOLD WHAT'S
HAPPENING, WE'RE ACTUALLY BEING
ASKED, WHAT WOULD BE USEFUL FOR
YOU, WHAT ARE THE TOPICS, AND
HOW DO WE CREATE ACTUAL
BITE-SIZE INFORMATION?
AND I KNOW IN OUR NETWORK WHEN
WE PUT OUT NEWSLETTERS OR PUT ON
SOCIAL MEDIA, WE NEED LITTLE
SNPPETS, REALLY SOUND BITES THAT
ARE EASY TO DIGEST, BUT THE
IMPORTANT THING IS, ALL OF THESE
ORGANIZATIONS THAT WE WORK WITH
HAVE DOZENS OR HUNDREDS OF PEER
SPECIALISTS THAT ARE ACTUALLY
WANTING THIS INFORMATION TO HELP
TALK WITH THE PEOPLE THEY WORK
WITH, THAT THEY'RE HELPING,
BECAUSE IT GIVES THEM HOPE.
YOUR RESEARCH IS GIVING THEM
HOPE THAT THEY CAN GET BETTER,
THAT THEIR BRAINS CAN CHANGE.
I KNOW WHEN I FIRST WORKED AS A
PERSON IN RECOVERY COMING INTO
THIS FIELD, I HAD NO IDEA THAT
THERE WAS A GROUP OF RESEARCHERS
OUT THERE THAT WERE TALKING
ABOUT ME.
THAT MY BRAIN WAS GOING TO GET
BETTER THE LONGER I STAYED AWAY
FROM THAT DRUG, THERE WOULD BE
CHEMISTRY CHANGES.
AND I USE THE BRAIN SLIDES IN
TRAININGS BECAUSE IT SHOWS
PEOPLE IN RECOVERY AND THE
PEOPLE THAT WORK WITH THEM, THAT
THERE'S HOPE.
IF I COULDN'T REMEMBER SOMETHING
WHILE I WAS ACTIVE IN ADDICTION
OR TAKING A LOT OF RISKS, ALL OF
THOSE THINGS THAT HAPPEN WHEN
YOUR BRAIN GETS IMPACTED, NOW I
KNOW IF I KEEP DOING THIS AND
STAY AWAY FROM THE ALCOHOL OR
DRUGS, IT WILL GET BETTER.
SO, SO MUCH OF WHAT YOU DO IS
REALLY ABOUT HOPE.
I AM NOT DOING WELL WITH THESE
SLIDES.
OKAY, EMPOWERING PEOPLE WITH
LIVED EXPERIENCE.
AS I SAID, YOU KNOW, THE
ORGANIZATIONS THAT WE WORK WITH
HAVE PROGRAMS IN EMERGENCY
DEPARTMENTS, IN DRUG COURTS, IN
ALL KINDS OF PLACES THEY'RE D
DOING HARM REDUCTION, THEY'RE
DOING RECOVERY SUPPORT SERVICES.
THEY OFTEN NEED THIS INFORMATION
TO INFLUENCE PUBLIC POLICY IN
THEIR OWN COMMUNITIES,
EVERYWHERE FROM A ZONING BOARD
TO CITY COUNCIL TO THEIR STATE
LEGISLATURE AND TO CAPITOL HILL.
SO THIS INFORMATION AND BRINGING
THIS TO PEOPLE WITH LIVED
EXPERIENCE IS REALLY CRITICAL.
WE ARE REALLY PROUD TO BE A
PARTNER IN THIS INITIATIVE
WORKING WITH THE OTHER MEMBERS
HERE.
I THINK THAT MOSTLY WHEN WE HAVE
THE TOOLS IN OUR TOOLBOX, WE CAN
DO SO MUCH MORE AND REALLY BRING
THAT HOPE TO COMMUNITIES.
SO THAT AS JESS MENTIONED, THERE
IS 11 PANELS WITH PEOPLE WITH
LIVED EXPERIENCE WHEN THAT WAS
FIRST CREATED, WE WERE INVITED
TO HELP FIND PEOPLE TO BE ON
THOSE PANELS.
SO HAVING A NATIONAL NETWORK AND
PUTTING THAT INFORMATION OUT
THERE REALLY HELPED TO GET THE
PEOPLE FROM DIVERSE COMMUNITIES
REPRESENTING ALL PARTS OF THE
COUNTRY ON THOSE PANELS.
I WANT TO LEAVE YOU WITH A FEW
COMMENTS JUST TO SAY ON BEHALF
OF THE RECOVERY COMMUNITY AND
FACES & VOICES OF RECOVERY,
THANK YOU FOR THE WORK THAT YOU
DO.
IT'S SO IMPORTANT THAT WE HAVE
THIS RESEARCH.
I WANTED TO SAY THAT HEAL
CONNECTIONS IS CRITICAL TO
REALLY SHARE THIS INFORMATION
AND BRING PEOPLE TOGETHER ACROSS
THIS WORK, AND HELP THEM BE
AWARE WHAT THE -- ABOUT THE
SCIENCE OF ADDICTION AND
RECOVERY, THAT THERE IS WORK
BEING DONE OUT THERE, AND
ULTIMATELY THIS REALLY BRINGS
HOPE TO A WHOLE COMMUNITY OF
PEOPLE THAT KNOW THAT YOU'RE
WORKING TO HELP FUTURE
GENERATIONS.
SO THANK YOU.
>> THANK YOU SO MUCH.
SO GRATEFUL FOR ALL OF OUR
ASSOCIATION PARTNERS.
YOU CAN SEE WHY THIS IS -- THESE
ARE SEVERAL OF OUR 16
ORGANIZATIONS THAT MAKE THIS
WORK HAPPEN MONTHLY, AND WE HAVE
THE BEST JOB BEING ABLE TO
COORDINATE WITH ALL OF THEM.
THEIR INPUT HAS REALLY MADE THIS
POSSIBLE TO GET REAL INFORMATION
INTO DIFFERENT HANDS AND
COMMUNITIES CAN BENEFIT FROM IT.
SO WE HAVE A LITTLE BIT OF TIME
FOR ANY Q & A, ANY QUESTIONS
THAT FOLKS MIGHT HAVE FOR ANY OF
OUR ASSOCIATION PARTNERS OR
ABOUT HEAL CONNECTIONS.
WE ALSO HAVE CARDS IF YOU'RE
INTERESTED IN GETTING LINED UP
TO WORK ON A TRANSLATION OF YOUR
STUDY.
ALL RIGHT, WE HAVE A QUESTION.
>> HI.
MY NAME IS INDITA.
I'M ON THE HEAL INITIATIVE
INDIGENOUS PANEL.
WE HAVE SOME WONDERFUL
FACILITATORS, SPECIAL SHOUTS OUT
TO EDEN AND TYRUS.
THEY DO A PHENOMENAL JOB.
[APPLAUSE]
ALSO ASHLEY IS WONDERFUL AS WE
WELL.
GOING DEEPER THAN THAT,
ESPECIALLY COMING HERE, I KNOW
I'VE HEARD AND ALSO FEEL THAT
THERE'S A GREAT DESIRE FOR THE
PEOPLE ON THE PANELS TO KIND OF
HAVE A DEEPER CONNECTION SO TO
SAY, LIKE WE KNOW THE PEOPLE
THAT WE SPEAK DIRECTLY TO, BUT I
THINK FOR A LOT OF US, WE WORK
IN MEDICAL SCIENCE OR HAVE THE
ASPIRATIONS TO.
WHAT DO ANY OF YOU THINK WOULD
BE A GREAT SOLUTION TO KIND OF
BREAK THAT BARRIER DOWN BECAUSE,
YOU KNOW, BEING A SCIENTIST,
BEING THE PERSON ACTUALLY DOING
THE DATA, ALL OF THAT STUFF,
SOMEHOW I KNOW OUR LIVED
EXPERIENCE, US AS PEOPLE, Y'ALL
AS PEOPLE, WE HAVE THE COMMON
EXPERIENCE OF THE HUMAN
EXPERIENCE.
SO HOW DO WE BRIDGE THAT GAP?
>> I LOVE THAT IDEA, AND THANK
YOU FOR YOUR SERVICE ON THE
PANEL AND FOR BEING HERE.
IT'S SO WONDERFUL.
ONE EXCITING THING WE'RE WORK ON
IN HEAL CONNECTIONS IS TO
ACTUALLY START TAILORING EVEN
FURTHER ALL OF THESE AMAZING
KNOWLEDGE TRANSLATION PIECES OF
SCIENCE FOR YOU.
OUR LEADERS ARE INFLUENCERS IN
OUR COMMUNITY, OUR PANELS, EVEN
SOME OF THE LEADERS AND MEMBERS
OF OUR ASSOCIATION PARTNERS, SO
WE CAN HAVE SORT OF AN
INFLUENCER STRATEGY.
AND ALSO FOLLOWING THAT SAME
RECIPE WE'VE BUILT.
WE WANT TO MAKE SURE THAT WE GET
THE COU CONTENT RIGHT, THAT IT S
FOR YOU, HOW DO YOU NEED IT, DO
YOU LIKE A VIDEO EXPLAINER, DO
YOU WANT TO PASS OUT A FLYER, DO
YOU NEED TO HAVE AN INFOGRAPHIC,
IS THIS ABOUT A LAY PERSON
SUMMARY?
SO WE'RE MAKING A PRIORITY TO
START VENTURING INTO THAT LANE
SO WE CAN BUILD BETTER PRODUCTS
FOR ALL OF OUR LEADERS WITH
LIVED EXPERIENCE TO HELP US GET
INFORMATION OUT ABOUT NEW
SCIENCE AND NEW INTERVENTIONS,
SO GIVE US SIX WEEKS AND WE'RE
GOING TO HAVE A TOOLBOX FOR YOU.
>> I CAN'T WAIT TO OPEN THE
SURVEY IN MY EMAIL.
WONDERFUL.
>> NORA, DO YOU HAVE A QUESTION?
>> I HAVE A QUESTION AND IT'S A
MESSAGE THAT'S BEEN GIVEN TO ME
AS I GO ON SPEAKING FORUMS.
WE WILL SAY, YES, WE HEAR YOU
TALK ALL THE TIME, BUT WE ARE
CONCERNED THAT AMONG THE GROUPS
THAT YOU DON'T PAY ATTENTION TO
ARE PEOPLE THAT ARE STILL
LIVING -- TAKING DRUGS, THAT ARE
NOT IN TREATMENT, THAT ARE NOT
IN RECOVERY, AND FOR WHICH
NONETHELESS RESEARCH TO HELP
THEM KEEP THEM ALIVE.
AND SO I'VE BEEN SURROUNDED BY
PEOPLE THAT HAVE MADE THIS POINT
VERY, VERY STRONGLY, AND I DO
BELIEVE THAT IT BEHOOVES US TO
TRY TO REACH TO THEM ALSO TO
UNDERSTAND, FOR EXAMPLE, WHAT
COULD BE HELPFUL TO BRING THEM
EVENTUALLY TO TREATMENT, WHAT
WOULD BE HELPFUL TO KEEP THEM
ALIVE.
AND ALSO WHAT IS IT THAT WE CAN
LEARN FROM THEIR EXPERIENCES IN
TERMS OF AREAS THAT WE MAY HAVE
NEGLECTED.
SO I DID WANT TO MAKE THAT
POINT, AND THAT'S WHY I'M VERY,
VERY SPECIFIC WHEN WE SPEAK
ABOUT PEOPLE WITH LIVED
EXPERIENCE, THAT IT'S ALSO WITH
LIVING EXPERIENCE, AND THAT WE
HAVE ABSOLUTELY PEOPLE THAT ARE
IN PAIN, BUT I DON'T THINK THAT
WE HAVE BEEN SO SENSITIVE ABOUT
THE ISSUE OF PEOPLE THAT ARE
STILL VERY, VERY MUCH STRUGGLING
WITH DRUGS AND ARE NOT READY TO
GO INTO TREATMENT.
AND THEY DO DESERVE TO BE HERE.
>> ABSOLUTELY.
>> YOU KNOW, THAT IS SUCH AN
IMPORTANT POINT, AND JUST ONE
THING THAT HAS COME UP A FEW
TIMES IN ME HEARING THE
PRESENTATIONS THIS WEEK.
WE NEED TO UNDERSTAND WHAT THE
ACTUAL GOAL IS AND WHAT IT
REALLY MEANS TO MEET SOMEONE
WHERE THEY'RE AT.
YOU KNOW, PART OF THE PROGRAM
THAT WE HAVE IN OUR EMERGENCY
ROOM IS NOT TO GET THE PATIENT
FROM BEDSIDE TO A TREATMENT
PROGRAM.
IT IS TO INTRODUCE THE IDEA OF
RECOVERY.
AND THAT MIGHT BE THE TIME THEN,
IT MIGHT BE THE TIME LATER, BUT
MEETING THEM WHERE THEY'RE AT,
AND REALLY HAVING THE GOAL BE
RECOVERY AND RECOVERY SUPPORT.
WE DON'T MEASURE SUCCESS BY HOW
MANY PATIENTS WE GET TO
TREATMENT.
IT IS BY HOW MANY PEOPLE THAT
STAY CONNECTED WITH US AND
ENGAGE US IN THAT RECOVERY
PROCESS.
THE OTHER THING, TOO, IS THE
RESEARCH AROUND THOSE
INDIVIDUALS.
I THINK -- I ACTUALLY SAW A
POSTER, I THINK, IN THE OTHER
ROOM ON THIS.
REALLY EDUCATING PEOPLE HOW
THEIR PARTICIPATION INFORMS AND
HELPS THE NEXT PERSON.
THAT IS A MAIN TENET OF
RECOVERY.
YOU HAVE TO GIVE TO KEEP IT.
IF YOU CAN TRANSLATE THAT SAME
PASSION AND THAT SAME COMMITMENT
TO RESEARCH, I GIVE MYSELF TO
THE RESEARCH TO HELP THE NEXT
PERSON, I THINK WE'LL HAVE MUCH
BETTER INCLUSION AND
PARTICIPATION.
>> ONE OTHER QUICK ITEM TO ADD,
WE ARE, NORA, WORKING ON ADDING
A FEW ASSOCIATION PARTNERS IN
ADDITION TO THE -- WE HAVE THE
NATIONAL HARM REDUCTION
COALITION CURRENTLY PART OF OUR
DISSEMINATION NETWORK, TALKING
TO THE DRUG USERS UNION, BOTH
NATIONAL ORGANIZATIONS AS WELL
AS COMMUNITY-BASED ORGANIZATIONS
TO MAKE SURE WE HAVE THE VOICE
OF THOSE WITH ACTIVE USE
DISORDERS ACROSS THE ENTIRE
CONTINUUM TO MAKE SURE THAT
WE'RE NOT MISSING THAT VOICE, I
AGREE IS JUST SO CRITICALLY
IMPORTANT.
ONE QUESTION HERE AND A I'M
GOING TO POP OVER HERE.
>> HI, EVERYBODY.
MY NAME IS KIMBERLY.
I'M FROM DALLAS, TEXAS.
I'M PART OF YOUR PANEL, YOUR
PAIN PANEL.
I'M LIVED EXPERIENCE.
HEY, EE DE EDEN, HEY, ASHLEY!
NEXT MONTH I'LL BE CELEBRATING
23 YEARS CLEAN OF DRUGS AND
ALCOHOL.
[APPLAUSE]
I HAVE WORKED IN SEVERAL
TREATMENT CENTERS, INCLUDING THE
TEXAS STATE JUSTICE DEPARTMENT
TEACHING RECOVERY CLASSES.
AND ONE OF THE THINGS THAT WE
FIND THAT REALLY HURTS OUR
COMMUNITY IS OPIOIDS.
YOU KNOW, WHEN WE GO INTO THE
FACILITIES, I HAVE SEVERAL CAR
ACCIDENTS, SO I HAVE LOWER BACK
PAIN, WHENEVER GI INTO A
DOCTOR -- I HAVE TO LET THE
DOCTOR KNOW THAT I'M IN
RECOVERY.
SO THEY CAN'T GIVE ME OPIOIDS.
IF THEY DO, THEN I RUN A RISK OF
RELAPSE.
THE DISEASE OF ADDICTION IS
REAL.
AND SO I WOULD LIKE TO SEE US
TAKE IT SERIOUSLY AND MAYBE LOOK
IN OTHER WAYS OF HANDLING PAIN
FOR THOSE OF US WITH THE DISEASE
OF ADDICTION, LIKE MAYBE
CHIROPRACTOR, MASSAGE THERAPY.
I DON'T KNOW, HOLISTIC -- YOU
KNOW, ANYTHING OTHER THAN --
STOP GIVING US ADDICTIVE
MEDICATION THAT'S GONNA SOMETIME
KILL US.
SO I'M HOPING THAT WE CAN FIND A
WAY TO LIKE -- I'M SO GRATEFUL
THAT I'M HERE, I'M GLAD WE'RE
ALL GETTING TOGETHER, WE ALL
HAVE A VOICE HERE, AND WE'RE NOT
LOOKED AT AS LESS THAN OR
THERE'S SOMETHING WRONG WITH US,
YOU KNOW, YOU'RE EPICALLY YOUR ,
NO, I HAVE A DISEASE, I TREAT
THE DISEASE ACCORDINGLY JUST AS
IF YOU TELL ME I HAVE THE
DISEASE OF CANCER, DO YOU LOOK
DOWN YOUR NOSE AT ME AND SAY I
HAVE CANCER?
YOU UNDERSTAND WHAT I'M SAYING?
SO WE HAVE TO HAVE OTHER WAYS OF
HANDLING PAIN MANAGEMENT WHEN IT
COMES TO THOSE OF US THAT HAVE
ADDICTION, I'VE ALWAYS HAD THE
DISEASE OF ADDICTION, I DON'T
OUT GROW THE DISEASE OF
ADDICTION.
IT IS WHAT IT IS, I'M GOING TO
HAVE IT THE REST OF MY LIFE.
SO I WOULD LIKE TO SEE SOME KIND
OF WAY THAT WE CAN ENHANCE OTHER
WAYS OF HANDLING PAIN FOR THOSE
OF US WITH THE DISEASE OF
ADDICTION OTHER THAN PUMPING US
FULL OF OPIOIDS.
THANK YOU.
>> THANK YOU SO MUCH.
WE WILL BE ON THE LOOKOUT FOR
ANY STUDIES THAT FIT THAT BILL
SO WE CAN GET IT OUT TO THE
HANDS OF THOSE WHO NEED THAT
INFORMATION.
ONE QUESTION HERE AND THEN WE'LL
WRAP IT UP WITH OUR FINAL
QUESTION.
>> OKAY, THANK YOU.
I MADE SOME NOTES AS WE WERE
GOING TO HELP ME KEEP ON TRACK.
SO EARLIER WE HEARD SOME STIGMA
IN LANGUAGE AND LABELS THAT ARE
COMMONLY USED FOR THOSE OF US
WITH SUBSTANCE USE AND
CO-OCCURRING DISORDERS.
THOSE WORDS YIELD SIGNIFICANT
INFLUENCE, AND THAT REQUIRES US
TO CHANGE HOW WE ARE SPEAKING IN
ORDER TO CHANGE PERCEPTIONS OF
THOSE OF US THAT DON'T
UNDERSTAND THE DISEASE OF
ADDICTION.
SO EMBRACING POSITIVE WORDS
HELPS BRIDGE SOME OF THE DIVIDE
THAT THOSE OF US IN AN ACTIVE
ADDICTION OR IN RECOVERY FEEL.
AS A MEMBER OF ONE OF THE LIVED
EXPERIENCE PANELS, WE'VE NOW HAD
20 DIFFERENT SESSIONS THAT WERE
OFFERED OVER THE LAST TWO DAYS,
BUT I NOTICED A LACK OF
OPPORTUNITIES FOR THE
INDIVIDUALS WITH LIVED
EXPERIENCE TO SPEAK.
YOU'VE NOW HEARD FROM THREE OF
US IN 10 MINUTES.
THE ONLY PERSON THAT WAS GIVEN
AN OPPORTUNITY TO SPEAK THAT
ALSO HAS LIVED EXPERIENCE WAS
TODAY, BUT HE WAS NOT PART OF
THE LIVED EXPERIENCE PANEL.
HE WAS PART OF A RESEARCH STUDY.
NONE OF THE SESSIONS WERE LED BY
ANYONE WITH LIVED EXPERIENCE.
AND THAT FEELS LIKE A MISSED
OPPORTUNITY.
WHILE I WAS INVITED TO SHARE MY
EXPERIENCES, I WASN'T INVITED TO
SHARE THAT WITH EVERYONE.
OR WITH MOST ATTENDEES.
THIS SEEMS LIKE A WASTE OF
RESOURCES, AND HIGHLIGHTS THE
NEED TO SHIFT FOCUS TOWARDS
SOLUTIONS RATHER THAN JUST
DISCUSSING PROBLEMS.
[APPLAUSE]
>> THANK YOU FOR THAT FEEDBACK.
THAT'S SO IMPORTANT THAT WE
CONTINUE TO IMPROVE AND CHANGE
HOW WE INCORPORATE ALL VOICES
INTO MEETINGS LIKE THIS, SO WE
KNOW A FEW OF THE FOLKS WHO
WORKED ON THIS CONFERENCE, SO WE
WILL TAKE THAT FEEDBACK AND MAKE
SURE THAT WE FIGURE OUT WAYS TO
BRING IN OUR PANEL MEMBERS IN
DIFFERENT WAYS.
ONE LAST QUESTION AND, AGAIN,
THANK YOU SO MUCH FOR STAYING
THROUGH THE END OF THIS
CONFERENCE AND LISTENING TO OUR
AMAZING PARTNERS.
>> HI.
CAN YOU GUYS HEAR ME OKAY?
>> YEAH.
>> ALL RIGHT.
MY NAME IS SPARKLE LINDSAY.
I'M A MOTIVATIONAL KEYNOTE
SPEAKER AND AN AUTHOR, AND I'M A
RECOVERY COACH PROFESSIONAL
FACILITATOR.
MY GOAL IS TO TRAIN COACHES TO
BE GREAT COACHES.
AND BEING ABLE TO COME HERE AND
BE PART OF THE HEAL INITIATIVE,
I WAS THE INDIGENOUS PANEL OR
PART OF THAT.
IT HAS BEEN EYE OPENING FOR ME.
I'M CURRENTLY FOUR YEARS NINE
MONTHS SOBER FROM ALCOHOL AND
ADDICTION.
[APPLAUSE]
THANK YOU.
AND ONE OF THE MAJOR THINGS I
CAN SAY ABOUT THIS IS THAT IT'S
BEEN WONDERFUL TO HEAR WHAT
RESEARCH IS HAPPENING.
IT REALLY IS.
I'M HAPPY TO BE A PART OF IT
WITH MY LIVED EXPERIENCE, BEING
ABLE TO PUT BOTH TOGETHER AND
BRIDGE THE GAPS TO THE
DISCONNECT THAT HAS BEEN
HAPPENING.
I BELIEVE THAT US BEING ABLE TO
SHARE OUR STORIES AND GIVE YOU
GUYS THE HEART OF YOUR DATA IS A
BEAUTIFUL THING, AND I'M GLAD TO
BE HERE TO BE A PART OF IT AND
I'M EXCITED TO BE ABLE TO SHARE
THIS LIVED EXPERIENCE WHETHER
IT'S BEING A RECOVERY COACH IN
THE EMERGENCY ROOM IN THE
JUSTICE SETTINGS, IN SCHOOLS,
ALL AROUND THE WORLD.
AND WE ARE THE ONES THAT ARE OUT
THERE, BOOTS ON THE GROUND,
WALKING ALONGSIDE THOSE, NOT
JUST MEETING THEM WHERE THEY'RE
AT, BUT MEETING OURSELVES WHERE
WE'RE AT.
THE IMPORTANCE IS TO UNDERSTAND
THAT ALL OF US THAT ARE GOING
THROUGH ADDICTION, WE HAVE TO
HAVE OUR OWN SET OF PROGRAMS T
TOO.
AND WHEN WE DO THAT, WE GIVE A
LOT OF ENERGY TO THOSE THAT ARE
FIGHTING AND LIVING AND TRYING
TO TAKE THEIR LIVES BACK.
SO WHEN WE KNOW THAT YOU GUYS
ARE DOING THE RESEARCH YOU'RE
DOING, AND YOU'RE SHOWING US
THAT IT'S POSSIBLE, THAT BELIEF
THAT THINGS CAN HAPPEN WHEN
PEOPLE GET TOGETHER, WHETHER
IT'S LIVED EXPERIENCE, WHETHER
IT'S RESEARCH, PUTTING THE ART
TO RECOVERY COACHING TOGETHER
AND ALSO BEING ABLE TO SEE
WHAT'S HAPPENING HERE SHOWCASES
TO THOSE THAT I'M TRAINING AND
THOSE THAT I'M WALKING ALONGSIDE
THAT THINGS WILL GET BETTER.
BUT I DO BELIEVE THAT WITH MY
STORY AND BEING ABLE TO TELL
THAT, YOU HAVE TO KNOW WHERE
YOUR RESEARCH IS GOING.
IT'S GOING TO THE HEART OF THE
PEOPLE WHO ARE OUT HERE SEEING
PEOPLE DROB D DROP DEAD FROM THE
MEDICINES.
THEY'RE DROPPING LIKE FLIES, AND
AS QUICK AS WE'RE TRYING TO GET
THINGS TOGETHER IS AS QUICK AS
WE'RE LOSING THEM.
I WAS ONE THAT DROPPED DEAD.
AND I'M HERE.
SO THE WORK WE'RE DOING, AND THE
WORK THAT WE'RE BRINGING
TOGETHER IS SO IMPORTANT IN A
WORLD RIGHT NOW THAT IS NOT JUST
BATTLING A WORLD EPIDEMIC, BUT
WE'RE BATTLING EVERYTHING ELSE.
PEOPLE GETTING OUT OF
INCARCERATION, AFTER 30 YEARS,
NOT KNOWING WHAT TO LOOK FORWARD
TO, BUT WE HAVE COACHES THAT ARE
STANDING OUTSIDE, WAITING TO
WALK WITH THEM.
AND WE HAVE COACHES WAITING
INSIDE THAT ARE TRYING TO HELP
THEM IN THE JUSTICE SETTINGS AS
WELL.
THE PROCESS IS MOVING FORWARD
AND IT'S BEAUTIFUL.
AND FOR ME, LOOKING AT THE FACT
THAT THE COACHES NOW NEED PEOPLE
TO WALK WITH THEM AND THEY NEED
TO KNOW THAT RESOURCES ARE
THERE, FOR THEM TO LEAD AND TO
GUIDE WITH POSITIVITY, TO
UNDERSTAND THINGS LIKE STIGMAS
AND LABELS, AND TO UNDERSTAND
THAT IF WE TALK WITH POSITIVITY,
AND WE USE OUR WORDS WITH THE
POWER OF INTENT, WE CAN DO
ANYTHING.
SO I JUST WANT TO SAY AGAIN
THANK YOU GUYS SO MUCH FOR
ALLOWING US TO COME IN HERE,
SHARE OUR STORIES.
WE'D LOVE TO SHARE OUR STORIES
MORE, GIVE YOU MORE DATA, MORE
INFORMATION, COME TOGETHER AND
BE FORCES TO BE RECKONED WITH
FOR OUR WORLD RIGHT NOW THAT
NEEDS US.
THANK YOU.
[APPLAUSE]
>> THANK YOU SO MUCH.
AND JUST A BIG THANK YOU TO THE
LEADERSHIP AT NIDA AND NINDS AND
NIH THAT MAKE CONNECTIONS IN
THIS WORK POSSIBLE.
IT REALLY IS SO AMAZING TO SEE
WHAT THE RESULTS ARE WHEN WE PUT
THIS INFORMATION INTO THE HANDS
OF THOSE WITH LIVED EXPERIENCE
AND STAKEHOLDERS AND THANK YOU
SO MUCH TO ALL OF OUR GREAT
PANELISTS TOO AND THEIR
PARTNERSHIP.
>> SO THANK YOU TO OUR HEAL
CONNECTIONS PANELISTS AND FOR
ALL THAT AUDIENCE PARTICIPATION.
THAT WAS GREAT.
I KEEP FEELING MORE OPTIMISTIC
AND INSPIRED AFTER EVERY SESSION
I HEAR HERE TODAY.
SO TO CLOSE THE MEETING, WE HAVE
DR. LANGEVIN, DIRECTOR OF THE
NATIONAL CENTER FOR
COMPLEMENTARY AND INTEGRATIVE
HEALTH, AND SHE'S GOING TO
PROVIDE SOME CLOSING REMARKS,
INCLUDING RECOGNIZING OUR 2024
HEAL AWARDEES, AS WELL AS THEMES
THAT AROSE DURING THIS YEAR'S
HEAL MEETING.
SO PLEASE WELCOME DR. LANGEVIN.
>> WELL, I'M SO THRILLED TO SEE
SO MANY OF YOU STILL HERE.
THIS IS FANTASTIC!
I'M GOING TO BE QUICK BECAUSE,
YOU KNOW, I'VE GOT FIVE MINUTES.
SO FIRST THE AWARDS.
IT'S MY GREAT PLEASURE TO --
WE'VE ALREADY HEARD THE
TRAILBLAZER AWARDS EARLIER THIS
AFTERNOON.
BUT I NOW WOULD LIKE TO
RECOGNIZE THE 2024 NIH HEAL
INITIATIVE AWARDEES IN SEVERAL
SPECIAL CATEGORIES.
THE FIRST CATEGORY IS
MENTORSHIP.
I'M GOING TO HOPEFULLY SEE THIS.
RIGHT.
THESE ARE -- HEAL HAS AWARDED
SIX RESEARCHERS THE AWARD FOR
MENTORSHIP.
RESEARCHERS HAVE SHOWN
EXCEPTIONAL COMMITMENT TO THE
MENTORING OF EARLY CAREER
SCIENTISTS IN THE PAIN AND
ADDICTION RESEARCH FIELD.
SO THESE AWARDS GO TO:
DR. ASHLI SHEIDOW.
PERHAPS IF SOME OF YOU ARE STILL
HERE, YOU CAN STAND UP AND BE
RECOGNIZED.
YAY!
THERE WE GO.
DR. SHEIDOW IS SENIOR RESEARCH
SCIENTIST WITH CHE CHESTNUT HILL
HEALTH SYSTEMS.
DR. AARON FOX, ASSOCIATE
PROFESSOR OF MEDICINE.
THERE WE GO.
AT THE ALBERT EINSTEIN COLLEGE
OF MEDICINE.
DR. DAVID SMELSON.
HERE?
PROFESSOR OF MEDICINE AT
UNIVERSITY OF MASSACHUSETTS,
CHAN MEDICAL SCHOOL.
DR. KATHLEEN SLUKA.
PROFESSOR OF PHYSICAL THERAPY
AND REHABILITATION SCIENCE
PROGRAM AT UNIVERSITY OF IOWA.
DR. DAN CLAUW.
PROFESSOR AT THE UNIVERSITY OF
MICHIGAN.
DR. CLAUDIA CAMPBELL.
PROFESSOR OF MEDICINE AT JOHNS
HOPKINS UNIVERSITY.
THANK YOU, ALL OF YOU, FOR BEING
SUCH GOOD MENTORS.
NEXT, HEAL HAS AWARDED TWO
RESEARCHERS THE HEAL AWARD FOR
INTERDISCIPLINARY COLLABORATION.
THESE RESEARCHERS ARE BRIDGING
RELATIONSHIPS -- BRINGING --
BRIDGING, EXCUSE ME,
RELATIONSHIPS ACROSS THE FIELD
OF SCIENCE RESULTING IN
INTERDISCIPLINARY AND
CUTTING-EDGE RESEARCH.
DR. KIMBERLY FRYER.
OBSTETRICS AND GYNECOLOGY AT
UNIVERSITY OF SOUTH FLORIDA, AND
DR. CECELIA VALRIE, ASSOCIATE
PROFESSOR AT VIRGINIA
COMMONWEALTH UNIVERSITY.
NEXT, HEAL HAS AWARDED FOUR
RESEARCHERS THE HEAL AWARD FOR
COMMUNITY PARTNERSHIP.
EXCEPTIONAL COMMITMENT TO THE
DEVELOPMENT OF COMMUNITY
PARTNERSHIPS CHARACTERIZED BY
RESPECT, EQUITY, AND MUTUAL
BENEFIT.
MARIA ISABELLA NATALE CASTILLO.
THE CLINICAL RESEARCH ASSISTANT
AT BOSTON CHILDREN'S HOSPITAL AT
HARVARD MEDICAL SCHOOL.
DR. LARA COUGHLIN.
ASSISTANT PROFESSOR AT
UNIVERSITY OF MICHIGAN.
DR. DOUGLAS KENNEDY.
ASSISTANT PROFESSOR AND FACULTY
RESEARCH FELLOW IN INTEGRATIVE
HEALTH AND WELL-BEING RESEARCH
PROGRAM AT UNIVERSITY OF
MINNESOTA.
DR. ISABEL ROTH.
RESEARCH ASSISTANT PROFESSOR,
UNIVERSITY OF NORTH CAROLINA AT
CHAPEL HILL.
AND FINALLY, HEAL HAS AWARDED
FOUR RESEARCHERS THE HEAL AWARD
FOR EXCELLENCE IN RESEARCH.
THESE RESEARCHERS ARE LEADING
EXEMPLARY RESEARCH THAT HAS HAD
A TRANSFORMATIVE IMPACT ON THE
PAIN AND ADDICTION RESEARCH
FIELD.
DR. NABILA EL-BASSEL, PROFESSOR
AT COLUMBIA UNIVERSITY.
DR. ALI REZAI, WEST VIRGINIA
UNIVERSITY.
DR. WILLIAM MARRAS, DIRECTOR OF
THE SPINE RESEARCH INSTITUTE AT
OHIO STATE UNIVERSITY.
AND DR. PRASAD SHIRVALKAR,
UNIVERSITY OF CALIFORNIA
SAN FRANCISCO.
LASTLY, I WOULD LIKE TO
RECOGNIZE THE THREE PLANNING
COMMITTEES THAT SHAPED THIS
YEAR'S MEETING.
THESE COMMITTEES SHARE THEIR
TIME AND EXPERTISE TO ADVISE ON
SESSION THEMES, FORMATS, AND
SPEAKER.
FIRST, THE RESEARCHER PLANNING
COMMITTEE.
THE NIH SCIENTIFIC PLANNING
COMMITTEE.
AND THE COORDINATING COMMITTEE,
TIRELESS WORK.
THANK YOU.
NOW LET ME HAVE JUST A COUPLE
MINUTES TO SHARE JUST A FEW
THOUGHTS.
THIS HAS BEEN SUCH AN INSPIRING
MEETING, REALLY.
YOU REALLY FEEL THAT YOU'RE SORT
OF -- SCIENCE MEETS HUMAN, YOU
KNOW, AT MEETINGS LIKE THIS.
AND WE'VE HEARD SO MANY
INSPIRING COMMENTS.
OBVIOUSLY WE HAD SOME EXCITING
SCIENCE.
I MEAN, A MEETING LIKE THIS
WITHOUT SCIENCE WOULDN'T QUITE
CUT IT AND WE DID GET SOME
EXCITING NEW DISCOVERY, SO MANY
EXCITING POSTERS, BIOMARKERS,
TARGETS FOR DRUGS.
BUT IN ADDITION TO THAT, I THINK
WHAT WAS REALLY REMARKABLE AT
THIS MEETING IS A REAL SENSE OF
MAKING THESE CONNECTIONS AT SO
MANY MULTIPLE LEVELS.
CONNECTING, FIRST OF ALL
BUILDING RELATIONSHIPS.
THAT'S WHY YOU'RE HERE, RIGHT?
THAT'S WHY WE COME TO MEETINGS
LIKE THIS, IS TO BE TOGETHER,
AND ALSO THE HEAL PURPOSE
NETWORK, WHICH IS REALLY
EXTENDING THE INTENT OF MAKING
THESE CONNECTIONS SO FAR BEYOND
A ROOM SUCH AS THIS, AND SO THIS
IS REALLY WHERE HEAL HAS PUT A
LOT OF EFFORT.
AND I THINK IT'S BEGINNING TO
SHOW THAT YOU ALL ARE GELLING
INTO A COMMUNITY.
YOU CAN FEEL IT.
THE OTHER PLACE WHERE
CONNECTIONS ARE SO IMPORTANT, OF
COURSE, IS MAKING THESE
PARTNERSHIPS, RIGHT, THROUGH THE
RESEARCH NETWORKS.
WE'VE HAD BEAUTIFUL EXAMPLES
THROUGH THE JCOIN HEALING
COMMUNITIES AND NCRU
PRESENTATIONS WHERE THESE
EFFORTS TO REALLY CONNECT WITH
COMMUNITIES THAT ARE IN NEED OF
THIS RESEARCH SO BADLY.
FINALLY, THERE WAS THESE VERY
INSPIRING COMMENTS, ESPECIALLY
JUST RECENTLY, JUST IN THIS LAST
SESSION, ON CONNECTING WITH
PEOPLE WITH LIVED EXPERIENCES
AND HOW THESE PEOPLE WITH LIVED
EXPERIENCES ARE MAKING THESE
CONNECTIONS THEMSELVES ALREADY
THROUGH THEIR WORK, PEER
SUPPORT, WE HEARD THE GENTLEMAN
TALKING ABOUT THIS FROM THE
V.A., SO IMPORTANT, AND AS
RECOVERRECOVERY COACHES.
THIS IS WHERE WE NEED TO DO EVEN
MORE TO HARNESS ALL THE POWER
THAT'S ALREADY EXISTING IN THE
COMMUNITY AND BRING IT TOGETHER
WITH THE RESEARCH.
THIS IS WHERE WE'RE REALLY GOING
TO MAKE A DIFFERENCE, WE CAN ALL
WORK TOGETHER.
FINALLY, ANOTHER VERY IMPORTANT
CONNECTION IS THROUGH DATA,
SHARING THE DATA.
DO IT!
ALL THE RESEARCHERS OUT HERE, IF
THERE'S ANY RESEARCHER OUT HERE
THAT HAS NOT YET REGISTERED FOR
THE HEAL DATA SYSTEM, DO IT.
YOU WILL FEEL BETTER ONCE YOU DO
IT.
IT DOESN'T TAKE LONG.
I HEAR FROM JESSICA OVER A
HUNDRED PEOPLE VISITED THE BOOTH
TODAY.
THAT'S A GOOD SIGN.
WE REALLY WANT TO SEE AN UPTICK
IN THE NUMBER OF PEOPLE
REGISTERING FOR THE HEAL DATA
ECOSYSTEM.
ALSO THE POWER OF COMBINING DATA
SHARING WITH RESEARCH NETWORKS,
THAT WAS EVIDENT IN SO MANY OF
THE PRESENTATIONS, WHERE YOU CAN
SEE THAT POOLING DATA FROM
SEVERAL STUDY, SUCH AS FOR SOME
OF THE CLINICAL TRIAL NETWORKS
THAT ARE ORGANIZED BY INTO DA,
IT'S IMMENSE, THE POWER OF THIS
RESEARCH, WHEN WE WORK TOGETHER,
WE CAN DO MORE.
THIS TOPIC OF, AGAIN,
IMPLEMENTATION SCIENCE AGAIN
SPEAKS TO THESE CONNECTIONS.
RESEARCH IS NOT GOING TO DO ANY
GOOD IF IT DOESN'T GET
IMPLENTIED.
AND WE HEARD THIS LOUD AND CLEAR
ALL DAY LONG, YESTERDAY AND
TODAY.
SO THERE WAS SUCH TERRIFIC
SESSIONS, TOOL KITS, MAKE MAKING
IMPLEMENTATION SCIENCE
IMPLEMENTABLE.
IT'S NOT EASY TO DO.
SO USE THOSE TOOL KITS.
AND FINALLY, DISSEMINATION OF
THIS, THIS WONDERFUL
PRESENTATION TODAY ON THE HEAL
CONNECTIONS, BRINGING THE
SCIENCE AND I WAS STRUCK BY THE
COMMENTS OF -- THE LAST COMMENTS
BY MICHAEL LITTERER SAYING, THE
SCIENCE HERE WAS SO WELL
ALIGNED, I HAD NO IDEA.
THAT, TO ME, SAYS IT ALL.
THIS IS WHERE WE HAVE TO
REALLY -- AND THIS IS WHERE ALL
OF THIS DISSEMINATION IS GOING
TO MAKE THAT BIG A DIFFERENCE.
PEOPLE NEED TO KNOW ABOUT THIS
AWESOME WORK THAT EVERYBODY IS
DOING.
SO WE'LL KEEP WORKING ON IT.
AND I WANT TO JUST CLOSE BY JUST
SAYING THAT GOING BACK TO
DR. BERTAGNOLLI'S COMMENTS
YESTERDAY, OUR WORK IS NOT
FINISHED WHEN WE PUBLISH OUR
STUDIES.
OUR WORK WILL BE FINISHED WHEN
PEOPLE LIVE LONG, HEALTHY LIVES.
SO I WANT TO JUST END WITH THE
DEFINITION AND I'M GOING TO USE
MY SPEAKER'S PREROGATIVE IN
TALKING ABOUT HOW WE THINK AT
NCCIH ABOUT WHOLE PERSON HEALTH.
THE WAY WE DEFINE THIS IS
EMPOWERING INDIVIDUALS,
FAMILIES, COMMUNITIES, AND
POPULATIONS TO IMPROVE THEIR
HEALTH IN MULTIPLE
INTERCONNECTED DOMAINS.
BIOLOGICAL, BEHAVIORAL, SOCIAL,
AND ENVIRONMENTAL.
AND I WOULD ADD TO THAT,
SPIRITUAL.
BECAUSE IT'S AN IMPORTANT
COMPONENT OF ALL OF THIS.
RIGHT?
AND SO I THINK THAT, YOU KNOW,
THE MORE WE MAKE THIS ABOUT
HUMANS, THE MORE WE MAKE THIS
ABOUT WHOLE HUMANS, THE MORE THE
SCIENCE IS GOING TO BE SERVING
US ALL.
SO THANK YOU, IT'S BEEN A GREAT
MEETING, AND WE'LL SEE YOU NEXT
TIME.
>> SO THANK YOU, DR. LANGEVIN,
FOR YOUR COMMENTS AND TO ALL OF
THE PRESENTERS OVER THE LAST TWO
DAYS.
I WANT TO THANK DR. ERIC HUDAK,
MYCO-EMCEE, BUT I ALSO WANT TO
THANK ALL OF YOU WHO ATTENDED
BOTH VIRTUALLY AND IN PERSON.
YOU'VE CONTRIBUTED YOUR VALUABLE
EXPERTISE AND LIVING EXPERIENCE
AND IT'S GREATLY APPRECIATED.
FOR THOSE OF WHO YOU ARE
ATTENDING A SATELLITE MEETING
TOMORROW, JUST A REMINDER THOSE
ARE BEING HELD DOWNSTAIRS, AND
YOU CAN LOOK AT THE MAP AND THE
AGENDA TO KNOW WHERE TO GO AND
SAFE TRAVELS HOME AND HAVE A
GREAT EVENING. 4121 02:19:08,540 THANK YOU, EVERYONE.